

MCKESSON CORP
Form 10-Q
January 26, 2017
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2016

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 1-13252

McKESSON CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 94-3207296
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)

One Post Street, San Francisco, California 94104
(Address of principal executive offices) (Zip Code)
(415) 983-8300

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Edgar Filing: MCKESSON CORP - Form 10-Q

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

| Class | Outstanding as of December 31, 2016 |
|--------------------------------|-------------------------------------|
| Common stock, \$0.01 par value | 212,052,504 shares |

Table of Contents

McKESSON CORPORATION

TABLE OF CONTENTS

| Item | Page |
|--|------|
| <u>PART I—FINANCIAL INFORMATION</u> | |
| 1. <u>Condensed Consolidated Financial Statements</u> | |
| <u>Condensed Consolidated Statements of Operations</u> <u>Quarters and Nine Months Ended December 31, 2016 and 2015</u> | 3 |
| <u>Condensed Consolidated Statements of Comprehensive Income</u> <u>Quarters and Nine Months Ended December 31, 2016 and 2015</u> | 4 |
| <u>Condensed Consolidated Balance Sheets</u> <u>December 31, 2016 and March 31, 2016</u> | 5 |
| <u>Condensed Consolidated Statements of Cash Flows</u> <u>Nine Months Ended December 31, 2016 and 2015</u> | 6 |
| <u>Financial Notes</u> | 7 |
| 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u> | 29 |
| 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u> | 42 |
| 4. <u>Controls and Procedures</u> | 42 |
| <u>PART II—OTHER INFORMATION</u> | |
| 1. <u>Legal Proceedings</u> | 42 |
| 1A. <u>Risk Factors</u> | 42 |
| 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | 42 |
| 3. <u>Defaults Upon Senior Securities</u> | 43 |
| 4. <u>Mine Safety Disclosures</u> | 43 |
| 5. <u>Other Information</u> | 43 |
| 6. <u>Exhibits</u> | 44 |
| <u>Signatures</u> | 45 |

Table of Contents

McKESSON CORPORATION

PART I—FINANCIAL INFORMATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In millions, except per share amounts)

(Unaudited)

| | Quarter Ended | | Nine Months Ended | |
|---|---------------|-----------|-------------------|------------|
| | December 31, | | December 31, | |
| | 2016 | 2015 | 2016 | 2015 |
| Revenues | \$50,130 | \$47,899 | \$149,820 | \$144,206 |
| Cost of Sales | (47,318) | (45,027) | (141,345) | (135,642) |
| Gross Profit | 2,812 | 2,872 | 8,475 | 8,564 |
| Operating Expenses | (1,981) | (1,952) | (5,802) | (5,759) |
| Goodwill Impairment Charge | — | — | (290) | — |
| Operating Income | 831 | 920 | 2,383 | 2,805 |
| Other Income, Net | 23 | 13 | 65 | 43 |
| Interest Expense | (74) | (87) | (231) | (267) |
| Income from Continuing Operations Before Income Taxes | 780 | 846 | 2,217 | 2,581 |
| Income Tax Expense | (131) | (204) | (570) | (704) |
| Income from Continuing Operations | 649 | 642 | 1,647 | 1,877 |
| Income (Loss) from Discontinued Operations, Net of Tax | (3) | 5 | (117) | (11) |
| Net Income | 646 | 647 | 1,530 | 1,866 |
| Net Income Attributable to Noncontrolling Interests | (13) | (13) | (48) | (39) |
| Net Income Attributable to McKesson Corporation | \$633 | \$634 | \$1,482 | \$1,827 |
| Earnings (Loss) Per Common Share Attributable to McKesson Corporation | | | | |
| Diluted | | | | |
| Continuing operations | \$2.86 | \$2.71 | \$7.07 | \$7.86 |
| Discontinued operations | (0.01) | 0.02 | (0.51) | (0.05) |
| Total | \$2.85 | \$2.73 | \$6.56 | \$7.81 |
| Basic | | | | |
| Continuing operations | \$2.89 | \$2.74 | \$7.14 | \$7.95 |
| Discontinued operations | (0.02) | 0.02 | (0.52) | (0.04) |
| Total | \$2.87 | \$2.76 | \$6.62 | \$7.91 |
| Dividends Declared Per Common Share | \$0.28 | \$0.28 | \$0.84 | \$0.80 |
| Weighted Average Common Shares | | | | |
| Diluted | 222 | 232 | 226 | 234 |
| Basic | 221 | 230 | 224 | 231 |

See Financial Notes

Table of Contents

McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In millions)

(Unaudited)

| | Quarter Ended December 31, | | Nine Months Ended December 31, | |
|--|-------------------------------------|--------|--------------------------------------|---------|
| | 2016 | 2015 | 2016 | 2015 |
| Net Income | \$646 | \$647 | \$1,530 | \$1,866 |
| Other Comprehensive Income (Loss), Net of Tax | | | | |
| Foreign currency translation adjustments arising during period | (398) | (246) | (762) | (142) |
| Unrealized gains (losses) on cash flow hedges arising during period | (14) | (1) | (20) | 5 |
| Retirement-related benefit plans | 8 | 15 | 20 | (2) |
| Other Comprehensive Income (Loss), Net of Tax | (404) | (232) | (762) | (139) |
| Comprehensive Income | 242 | 415 | 768 | 1,727 |
| Comprehensive (Income) Loss Attributable to Noncontrolling Interests | 17 | 18 | 47 | (32) |
| Comprehensive Income Attributable to McKesson Corporation | \$259 | \$433 | \$815 | \$1,695 |

See Financial Notes

Table of Contents

McKESSON CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(In millions, except per share amounts)

(Unaudited)

| | December 31, 2016 | March 31, 2016 |
|--|----------------------|-------------------|
| ASSETS | | |
| Current Assets | | |
| Cash and cash equivalents | \$ 2,434 | \$4,048 |
| Receivables, net | 18,198 | 17,980 |
| Inventories, net | 16,121 | 15,335 |
| Prepaid expenses and other | 513 | 437 |
| Current assets held for sale | 2,002 | 635 |
| Total Current Assets | 39,268 | 38,435 |
| Property, Plant and Equipment, Net | 2,411 | 2,278 |
| Goodwill | 10,612 | 9,786 |
| Intangible Assets, Net | 3,583 | 3,021 |
| Other Noncurrent Assets | 2,000 | 3,003 |
| Total Assets | \$ 57,874 | \$56,523 |
| LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND EQUITY | | |
| Current Liabilities | | |
| Drafts and accounts payable | \$ 30,811 | \$28,585 |
| Short-term borrowings | 1,406 | 7 |
| Deferred revenue | 402 | 919 |
| Current portion of long-term debt | 1,748 | 1,610 |
| Other accrued liabilities | 3,113 | 3,288 |
| Current liabilities held for sale | 694 | 660 |
| Total Current Liabilities | 38,174 | 35,069 |
| Long-Term Debt | 5,969 | 6,497 |
| Long-Term Deferred Tax Liabilities | 2,884 | 2,734 |
| Other Noncurrent Liabilities | 1,684 | 1,809 |
| Redeemable Noncontrolling Interests | 1,311 | 1,406 |
| McKesson Corporation Stockholders' Equity | | |
| Preferred stock, \$0.01 par value, 100 shares authorized, no shares issued or outstanding | — | — |
| Common stock, \$0.01 par value, 800 shares authorized at December 31, 2016 and March 31, 2016, 273 and 271 shares issued at December 31, 2016 and March 31, 2016 | 3 | 3 |
| Additional Paid-in Capital | 6,037 | 5,845 |
| Retained Earnings | 9,663 | 8,360 |
| Accumulated Other Comprehensive Loss | (2,228 |) (1,561) |
| Other | (3 |) (2) |
| Treasury Shares, at Cost, 61 and 46 at December 31, 2016 and March 31, 2016 | (5,780 |) (3,721) |
| Total McKesson Corporation Stockholders' Equity | 7,692 | 8,924 |
| Noncontrolling Interests | 160 | 84 |
| Total Equity | 7,852 | 9,008 |
| Total Liabilities, Redeemable Noncontrolling Interests and Equity | \$ 57,874 | \$56,523 |

See Financial Notes

Table of Contents

McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

(Unaudited)

| | Nine Months Ended December 31, | |
|--|--------------------------------------|----------|
| | 2016 | 2015 |
| Operating Activities | | |
| Net income | \$1,530 | \$1,866 |
| Adjustments to reconcile to net cash provided by operating activities: | | |
| Depreciation and amortization | 663 | 671 |
| Goodwill impairment charge | 290 | — |
| Deferred taxes | 122 | 30 |
| Share-based compensation expense | 109 | 113 |
| Charges (credits) associated with last-in-first-out inventory method | (151) | 215 |
| Loss (gain) from sale of businesses | 113 | (103) |
| Other non-cash items | 50 | 139 |
| Changes in operating assets and liabilities, net of acquisitions: | | |
| Receivables | (654) | (1,667) |
| Inventories | (374) | (2,397) |
| Drafts and accounts payable | 1,891 | 1,695 |
| Deferred revenue | (58) | (66) |
| Taxes | 52 | 114 |
| Other | (274) | (44) |
| Net cash provided by operating activities | 3,309 | 566 |
| Investing Activities | | |
| Payments for property, plant and equipment | (246) | (272) |
| Capitalized software expenditures | (123) | (145) |
| Acquisitions, net of cash and cash equivalents acquired | (4,174) | (25) |
| Proceeds from/(payment for) sale of businesses, net | (91) | 204 |
| Restricted cash for acquisitions | 935 | — |
| Other | 80 | 10 |
| Net cash used in investing activities | (3,619) | (228) |
| Financing Activities | | |
| Proceeds from short-term borrowings | 2,803 | 1,532 |
| Repayments of short-term borrowings | (1,405) | (1,668) |
| Repayments of long-term debt | (392) | (996) |
| Common stock transactions: | | |
| Issuances | 89 | 97 |
| Share repurchases, including shares surrendered for tax withholding | (2,060) | (960) |
| Dividends paid | (192) | (179) |
| Other | 12 | (73) |
| Net cash used in financing activities | (1,145) | (2,247) |
| Effect of exchange rate changes on cash and cash equivalents | (159) | (26) |
| Net decrease in cash and cash equivalents | (1,614) | (1,935) |
| Cash and cash equivalents at beginning of period | 4,048 | 5,341 |

| | | |
|--|---------|---------|
| Cash and cash equivalents at end of period | \$2,434 | \$3,406 |
|--|---------|---------|

See Financial Notes

6

Table of Contents

McKESSON CORPORATION
FINANCIAL NOTES
(UNAUDITED)

1. Significant Accounting Policies

Basis of Presentation: The condensed consolidated financial statements of McKesson Corporation (“McKesson,” the “Company,” or “we” and other similar pronouns) include the financial statements of all wholly-owned subsidiaries and majority owned or controlled companies. For those consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as “Net Income Attributable to Noncontrolling Interests” on the condensed consolidated statements of operations.

We consider ourselves to control an entity if we are the majority owner of and have voting control over such entity.

We also assess control through means other than voting rights (“variable interest entities” or “VIEs”) and determine which business entity is the primary beneficiary of the VIE. We consolidate VIEs when it is determined that we are the primary beneficiary of the VIE. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method and our proportionate share of income or loss is recorded in Other Income, Net. All significant intercompany balances and transactions have been eliminated in consolidation including the intercompany portion of transactions with equity method investees.

The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and disclosures normally included in the annual consolidated financial statements.

To prepare the financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts may differ from these estimated amounts. In our opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods presented.

The results of operations for the quarter and nine months ended December 31, 2016 are not necessarily indicative of the results that may be expected for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies and financial notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2016 previously filed with the SEC on May 5, 2016 (“2016 Annual Report”).

Certain prior period amounts have been reclassified to conform to the current period presentation.

The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year.

Recently Adopted Accounting Pronouncements

Share-Based Payments: In March 2016, amended guidance was issued for employee share-based payment awards.

Under the amended guidance, all excess tax benefits (“windfalls”) and deficiencies (“shortfalls”) related to employee share-based compensation arrangements are recognized within income tax expense. Under the previous guidance, windfalls were recognized in additional paid-in capital (“APIC”) and shortfalls were only recognized to the extent they exceeded the pool of windfall tax benefits. The amended guidance also requires excess tax benefits to be classified as an operating activity in the statement of cash flows, rather than a financing activity. The amended guidance is effective for us commencing in the first quarter of 2018. Early adoption is permitted. We elected to early adopt this amended guidance in the first quarter of 2017. The primary impact of the adoption was the recognition of excess tax benefits in the income statement on a prospective basis, rather than APIC. As a result, discrete tax benefits of \$47 million were recognized in income tax expense in the first nine months of 2017. We also elected to adopt the cash flow presentation of the excess tax benefits prospectively commencing in the first quarter of 2017. None of the other provisions in this amended guidance had a material impact on our condensed consolidated financial statements.

Table of Contents

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Business Combinations: In the first quarter of 2017, we adopted amended guidance for an acquirer's accounting for measurement-period adjustments. The amended guidance eliminates the requirement that an acquirer in a business combination account for measurement-period adjustments retrospectively and instead requires that measurement-period adjustments be recognized during the period in which it determines the adjustment. In addition, the amended guidance requires that the acquirer record, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.

Fair Value Measurement: In the first quarter of 2017, we adopted amended guidance that limits disclosures and removes the requirement to categorize investments within the fair value hierarchy if the fair value of the investment is measured using the net asset value per share practical expedient. The amended guidance will primarily affect our fiscal 2017 annual disclosures related to our pension benefits. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.

Fees Paid in a Cloud Computing Arrangement: In the first quarter of 2017, we adopted amended guidance for a customer's accounting for fees paid in a cloud computing arrangement. The amended guidance requires customers to determine whether or not an arrangement contains a software license element. If the arrangement contains a software element, the related fees paid should be accounted for as an acquisition of a software license. If the arrangement does not contain a software license, it is accounted for as a service contract. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.

Debt Issuance Costs: In the first quarter of 2017, we adopted amended guidance for the balance sheet presentation of debt issuance costs on a retrospective basis. The amended guidance requires debt issuance costs related to a recognized debt liability to be reported on the balance sheet as a direct deduction from the carrying amount of that debt liability. The recognition and measurement guidance for debt issuance costs are not affected by the amended guidance. In August 2015, a clarification was added to this amended guidance that debt issuance costs related to line-of-credit arrangements can continue to be deferred and presented as an asset on the balance sheet. Upon adoption, unamortized debt issuance costs of \$40 million were reclassified primarily from other noncurrent assets to long-term debt at March 31, 2016.

Consolidation: In the first quarter of 2017, we adopted amended guidance for consolidating legal entities in which a reporting entity holds a variable interest. The amended guidance modifies the evaluation of whether limited partnerships and similar legal entities are VIEs and changes the consolidation analysis of reporting entities that are involved with VIEs that have fee arrangements and related party relationships. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

Business Combinations: In January 2017, amended guidance was issued to clarify the definition of a business to assist entities in evaluating whether transactions should be accounted for as acquisitions of assets or businesses. The amended guidance provides a practical screen to determine when an integrated set of assets and activities (collectively referred to as a "set") is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. If the screen is not met, the amended guidance requires that to be considered a business, a set must include an input and a substantive process that together significantly contribute to the ability to create output. The amended guidance is effective for us commencing in the first quarter of 2019 on a prospective basis. Early adoption is permitted in certain circumstances. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

Restricted Cash: In November 2016, amended guidance was issued that requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period

total amounts shown on the statement of cash flows. Transfers between cash and cash equivalents and restricted cash or restricted cash equivalents are not reported as cash flow activities in the statement of cash flows. The amended guidance is effective for us commencing in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

Table of Contents

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Consolidation: In October 2016, amended guidance was issued that requires a single decision maker of a VIE to consider indirect economic interests in the entity held through related parties that are under common control on a proportionate basis when determining whether it is the primary beneficiary of that VIE. This amendment does not change the existing characteristics of a primary beneficiary. The amended guidance becomes effective for us commencing in the first quarter of 2018 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

Income Taxes - Intra-Entity Transfers of Assets Other Than Inventory: In October 2016, amended guidance was issued to require entities to recognize income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amended guidance is effective for us commencing in the first quarter of 2019 on a modified retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments: In August 2016, amended guidance was issued to provide clarification on cash flow classification related to eight specific issues including contingent consideration payments made after a business combination and distributions received from equity method investees. The amended guidance is effective for us commencing in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

Financial Instruments - Credit Losses: In June 2016, amended guidance was issued, which will change the impairment model for most financial assets and require additional disclosures. The amended guidance requires financial assets that are measured at amortized cost, be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets. The amended guidance also requires us to consider historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amount in estimating credit losses. The amended guidance becomes effective for us commencing in 2021 and will be applied through a cumulative-effect adjustment to the beginning retained earnings in the year of adoption. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

Investments: In March 2016, amended guidance was issued to simplify the transition to the equity method of accounting. This standard eliminates the requirement that when an existing cost method investment qualifies for use of the equity method, an investor must restate its historical financial statements, as if the equity method had been used during all previous periods. Additionally, at the point an investment qualifies for the equity method, any unrealized gain or loss in accumulated other comprehensive income (loss) will be recognized through earnings. The amended guidance is effective for us prospectively commencing in the first quarter of 2018. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

Derivatives and Hedging: In March 2016, amended guidance was issued for derivative instrument novations. The amendments clarify that a novation, a change in the counterparty, to a derivative instrument that has been designated as a hedging instrument does not, in and of itself, require dedesignation of that hedging relationships provided all other hedge accounting criteria continue to be met. The amended guidance is effective for us commencing in the first quarter of 2018. The amended guidance allows for either prospective or modified retrospective adoption. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

Leases: In February 2016, amended guidance was issued for lease arrangements. The amended standard will require recognition on the balance sheet for all leases with terms longer than 12 months: a lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset,

which is an asset that represents the lessee's right to use, or control the use of, a specified asset for the lease term. The amended guidance is effective for us commencing in the first quarter of 2020, on a modified retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

Table of Contents

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Financial Instruments: In January 2016, amended guidance was issued that requires equity investments to be measured at fair value with changes in fair value recognized in net income and enhanced disclosures about those investments. This guidance also simplifies the impairment assessments of equity investments without readily determinable fair value. The investments that are accounted for under the equity method of accounting or result in consolidation of the investee are excluded from the scope of this amended guidance. The amended guidance will become effective for us commencing in the first quarter of 2019 and will be adopted through a cumulative-effect adjustment. Early adoption is not permitted except for certain provisions. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

Inventory: In July 2015, amended guidance was issued for the subsequent measurement of inventory. The amended guidance requires entities to measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The requirement would replace the current lower of cost or market evaluation. Accounting guidance is unchanged for inventory measured using last-in-first-out (“LIFO”) or the retail method. The amended guidance will become effective for us commencing in the first quarter of 2018. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.

Revenue Recognition: In May 2014, amended guidance was issued for recognizing revenue from contracts with customers. The amended guidance eliminates industry specific guidance and applies to all companies. Revenues will be recognized when an entity satisfies a performance obligation by transferring control of a promised good or service to a customer in an amount that reflects the consideration to which the entity expects to be entitled for that good or service. Revenue from a contract that contains multiple performance obligations is allocated to each performance obligation generally on a relative standalone selling price basis. The amended guidance also requires additional quantitative and qualitative disclosures. In March, April and May 2016, amended guidance was further issued including clarifying guidance on principal versus agent considerations, ability to choose an accounting policy election to account for shipping and handling activities that occur after the customer has obtained control of a good as an activity to fulfill the promise to transfer the good, and provided certain scope improvements and practical expedients. The amended standard is effective for us commencing in the first quarter of 2019 and allows for either full retrospective adoption or modified retrospective adoption. Early adoption is permitted but not prior to our first quarter of 2018.

While we are still in the process of assessing the anticipated impact of the amended standard on our condensed consolidated financial statements, for our Distribution Solutions Segment, we generally anticipate having substantially similar performance obligations under the amended guidance as compared with deliverables and units of account currently being recognized. Additionally, we intend to make policy elections within the amended standard that are consistent with our current accounting. We anticipate adopting this standard on a modified retrospective basis in the first quarter of 2019.

2. Proposed Healthcare Technology Net Asset Exchange

On June 28, 2016, McKesson entered into a contribution agreement as well as various other agreements (“Agreements”) with Change Healthcare Holdings, Inc. (“Change Healthcare”), a Delaware corporation, and others to form a joint venture (“New Company”). Under the terms of the Agreements, McKesson will contribute the majority of its McKesson Technology Solutions businesses (“Core MTS Business”) to the New Company. McKesson will retain its RelayHealth Pharmacy and Enterprise Information Solutions (“EIS”) businesses. Change Healthcare will contribute substantially all of its businesses to the New Company excluding its pharmacy switch and prescription routing businesses. The purpose of the transaction is to create a new healthcare information technology company, which will bring together the complementary strengths of the Core MTS Business and Change Healthcare to provide software and analytics, network solutions and technology-enabled services that will help customers obtain actionable insights,

exchange mission-critical information, control costs, optimize revenue opportunities, increase cash flow and effectively navigate the shift to value-based healthcare.

McKesson and Change Healthcare have agreed that they will take steps to launch an initial public offering of an entity holding equity in the New Company in the months following the close of the transaction, subject to market conditions. Thereafter, McKesson expects to exit its investment in the New Company in a transaction that is intended to qualify as a tax-free spin-off for U.S. federal income tax purposes under Section 355 of the Internal Revenue Code.

In connection with the transaction, the New Company has received \$6.1 billion of committed financing, including a \$1.2 billion bridge loan facility, from certain banks. The proceeds are expected to be utilized for the repayment of the existing debt of Change Healthcare, financing costs and payments to Change Healthcare shareholders and McKesson, including reimbursements of certain transaction-related expenses incurred by McKesson and Change Healthcare.

Table of Contents

McKESSON CORPORATION
 FINANCIAL NOTES (CONTINUED)
 (UNAUDITED)

On December 21, 2016, McKesson and Change Healthcare announced that it had received notification that the Department of Justice had closed its review and terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Subject to satisfaction of these other closing conditions, the acquisition is expected to close in the first half of calendar year 2017. Upon formation of the New Company, McKesson and Change Healthcare shareholders are expected to own approximately 70% and 30% of the New Company. The New Company will be jointly governed by McKesson and Change Healthcare shareholders. The Company refers to the foregoing transaction as “Healthcare Technology Net Asset Exchange”.

On January 5, 2017, McKesson and Change Healthcare announced that the companies decided the name of the New Company will be Change Healthcare.

During the third quarter and first nine months of 2017, we recorded \$31 million and \$58 million of expenses directly associated with this proposed transaction, which are primarily recorded in Operating Expenses within our Technology Solutions segment in the accompanying condensed consolidated statements of operations.

Assets and Liabilities Held for Sale

During the second quarter of 2017, the assets and liabilities of the Core MTS Business to be contributed to the New Company met the criteria to be classified as held for sale. The net asset exchange transaction does not meet the criteria to be reported as a discontinued operation as it does not constitute a significant strategic business shift. Accordingly, at December 31, 2016, \$1.9 billion of assets and \$0.7 billion of liabilities related to the Core MTS Business are included in “Current assets held for sale” and “Current liabilities held for sale” in the accompanying condensed consolidated balance sheet. Depreciation and amortization related to the long-lived assets ceased as of the date they were determined as held for sale.

The following table summarizes the carrying amounts of major classes of assets and liabilities held for sale:

December
 31, 2016
 Receivables,
 net \$ 433
 Other
 current
 assets \$ 607
 Goodwill
 Intangible
 assets,
 net \$ 93
 Other
 current
 assets \$ 176
 Current
 assets
 held for
 sale \$ 1,892

Deferred
\$ 482
revenue
Other
149
current
liabilities
Other
60
noncurrent
liabilities
Current
liabilities
\$ 603
for
sale

3. Goodwill Impairment

In conjunction with the proposed Healthcare Technology Net Asset Exchange, we are evaluating strategic options for our EIS business, which is a reporting unit within our McKesson Technology Solutions segment. In the second quarter of 2017, we recorded a provisional non-cash pre-tax charge of \$290 million (\$282 million after-tax) to impair the carrying value of this business' goodwill. We completed our analysis of the goodwill impairment assessment in the third quarter of 2017 and concluded that no further adjustment was needed. Most of the goodwill impairment is not deductible for income tax purposes. The impairment primarily resulted from a decline in estimated future cash flows.

Table of Contents

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

The goodwill impairment test requires us to compare the fair value of the reporting unit to the fair value of the reporting unit's net assets, excluding goodwill but including any unrecognized intangible assets, to determine the implied fair value of goodwill. The impairment charge was then determined by comparing the carrying value of the reporting unit's goodwill with its implied fair value of goodwill. At December 31, 2016, the remaining goodwill balance for this reporting unit was \$124 million. Refer to Financial Note 15, "Fair Value Measurements," for more information on this nonrecurring fair value measurement.

4. Business Combinations

During the first nine months of 2017, we completed our acquisitions of Rexall Health, Vantage Oncology Holdings LLC ("Vantage"), Biologics, Inc. ("Biologics"), UDG Healthcare Plc ("UDG") and J Sainsbury Plc ("Sainsbury"), as further discussed below.

In the first quarter of 2017, we adopted the amended accounting guidance for an acquirer's accounting for measurement period adjustments. Accordingly, as required, we now recognize all measurement period adjustments in the reporting period in which the adjustments are determined.

Rexall Health

On December 28, 2016, we completed our acquisition of Rexall Health of the Katz Group Canada, Inc. for cash purchase consideration of \$2.9 billion Canadian dollars (or, approximately \$2.1 billion U.S. dollars), which was funded from cash on hand. Rexall Health operates approximately 470 retail pharmacies in Canada, particularly in Ontario and Western Canada. As part of the transaction, McKesson agreed to divest stores in 26 local markets that the Competition Bureau of Canada (the "Bureau") identified during its review of the transaction. We do not anticipate any store closures as a result of these divestitures.

The acquisition of Rexall Health will enhance our capability to continue to deliver a broad range of pharmaceutical care and choice to Canadian consumers. Commencing in the fourth quarter of 2017, financial results for Rexall will be included in our North America pharmaceutical distribution and services business within our Distribution Solutions segment.

Total assets acquired and liabilities assumed, excluding goodwill and intangibles, were \$687 million and \$199 million. Approximately \$1.1 billion of the preliminary purchase price allocation has been assigned to goodwill, net of goodwill classified as held for sale, which primarily represents intangible assets that do not qualify as separate recognition. The amount of goodwill expected to be deductible for tax purposes is approximately \$860 million. Included in the preliminary purchase price allocation are acquired identifiable intangibles of \$656 million, net of intangibles classified as held for sale, primarily representing trade names and customer relationships. We are currently evaluating the expected lives of the identifiable intangibles. Additionally, we classified those stores that we agreed to divest under the agreement reached with the Bureau as held for sale as of the acquisition date. As a result, approximately \$110 million of assets and \$1 million of liabilities are included in "Current assets held for sale" and "Current liabilities held for sale" in the accompanying condensed consolidated balance sheet as of December 31, 2016.

Table of Contents

McKESSON CORPORATION
 FINANCIAL NOTES (CONTINUED)
 (UNAUDITED)

The following table summarizes the preliminary recording of the fair values of the assets acquired and liabilities assumed for the acquisition as of the acquisition date. Due to the recent timing and complexity of the acquisition, these amounts are provisional and subject to change as our fair value assessments are finalized.

Amounts
 Recognized
~~(16)~~
 Acquisition
 Date
 (Provisional)
~~Receivables~~
~~Inventory~~
 Other
 current
 assets,
 net
 of
 141
 cash
 and
 cash
 equivalents
 acquired
~~Goodwill~~
 Intangible
 656
 assets
 Other
~~Long-term~~
 assets
 Current
 (154)
 liabilities)
 Other
~~Long-term~~)
 liabilities)
 Fair
 value
 of
 net
 assets,
~~1,386~~
 cash
 and
 cash
 equivalents

165:
 Settlement
 of

pre-existing
payables
Purchase
consideration
paid
in
cash, 121
net
of
cash
acquired
Vantage & Biologics

On April 1, 2016, we acquired Vantage, which is headquartered in Manhattan Beach, California. Vantage provides comprehensive oncology management services, including radiation oncology, medical oncology, and other integrated cancer care services, through over 51 cancer treatment facilities in 13 states. The net purchase consideration of \$515 million was funded from cash on hand. On April 1, 2016, we also acquired Biologics for net purchase consideration of \$692 million, which was funded from cash on hand. Biologics is one of the largest independent oncology-focused specialty pharmacy in the U.S., and is headquartered in Cary, North Carolina. Financial results for these acquisitions since the acquisition date are included in our results of operations within our North America pharmaceutical distribution and services business, which is part of our Distribution Solutions segment. These acquisitions collectively enhance our specialty pharmaceutical distribution scale and oncology-focused pharmacy offerings, provide solutions for manufacturers and payers, and expand the scope of our community-based oncology and practice management services.

Table of Contents

McKESSON CORPORATION
 FINANCIAL NOTES (CONTINUED)
 (UNAUDITED)

The following table summarizes the preliminary recording of the fair values of the assets acquired and liabilities assumed for these two acquisitions as of the acquisition date:

| Amounts Previously Recognized (knof of Acquisition Date (Provisional) (1) | Measurement Period Adjustments | Amounts Recognized as of Acquisition Date (Provisional as Adjusted) |
|---|--------------------------------------|---|
| Receivables | \$ (7) | \$ 99 |
| Other current assets, net of 19 cash and cash equivalents acquired | — | 19 |
| Goodwill | (131) | 1,088 |
| Intangible 136 assets | 72 | 208 |
| Other 16 long-term assets | 37 | 113 |
| Current 117 liabilities |) (2) | (119) |
| Other 18 long-term liabilities |) (28) | (108) |
| Fair value of net assets, 1,359 less | (59) | 1,300 |
| cash and cash equivalents | | |
| Less: 62 Noncontrolling Interests | 59 | (93) |
| \$ 1,207 | \$ — | \$ 1,207 |

Fair
value
of
net
assets
acquired,
net
of
cash
and
cash
equivalents

(1) As reported on Form 10-Q for the quarter ended June 30, 2016.

During the first nine months of 2017, we recorded certain measurement period adjustments to the provisional fair value of assets acquired and liabilities assumed as of the acquisition date. The amounts as of the acquisition date are provisional and subject to change within the measurement period as our fair value assessments are finalized.

At December 31, 2016, approximately \$516 million and \$572 million of the adjusted preliminary purchase price allocations for Vantage and Biologics have been assigned to goodwill, which primarily reflects the expected future benefits of synergies upon integrating the businesses. Goodwill represents the excess of the purchase price and the fair value of noncontrolling interests over the fair value of the acquired net assets. Most of the goodwill is not expected to be deductible for tax purposes.

Included in the adjusted preliminary purchase price allocation are acquired identifiable intangibles of \$15 million and \$193 million for Vantage and Biologics. Acquired intangibles for Vantage primarily consist of \$7 million of non-competition agreements with a weighted average life of 4 years, and for Biologics primarily consist of \$170 million of trade names with a weighted average life of 9 years. The adjusted preliminary fair value of Vantage's noncontrolling interests as of the acquisition date was approximately \$93 million, which represents the portion of net assets of Vantage's consolidated entities that is not allocable to McKesson.

UDG

On April 1, 2016, we completed our acquisition of the pharmaceutical distribution businesses of UDG based in Ireland and the United Kingdom ("U.K.") with a net purchase consideration of €380 million (or, approximately \$431 million), which was funded with cash on hand. The acquired UDG businesses primarily provide pharmaceutical and other healthcare products to retail and hospital pharmacies. The acquisition of UDG expands our offerings and strengthens our market position in Ireland and the U.K. Financial results for UDG since the acquisition date are included in our results of operations within our International pharmaceutical distribution and services business, which is part of our Distribution Solutions segment.

Table of Contents

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

During the first nine months of 2017, we recorded certain measurement period adjustments to the provisional fair value of assets acquired and liabilities assumed as of the acquisition date. The net effect of the cumulative period adjustments was an increase in goodwill of approximately \$16 million from the provisional amounts as previously reported at June 30, 2016. Goodwill reflects the expected future benefits of synergies upon integrating the businesses. Most of the goodwill is not expected to be deductible for tax purposes. At December 31, 2016, the adjusted preliminary fair values of assets acquired and liabilities assumed as of the acquisition date, excluding goodwill and intangibles, were \$467 million and \$332 million. Included in the adjusted preliminary purchase price allocation are acquired identifiable intangibles of \$115 million primarily comprised of customer relationships with a weighted average life of 10 years. The amounts as of the acquisition date are provisional and subject to change within the measurement period as our fair value assessments are finalized.

Sainsbury

On August 31, 2016, we completed our acquisition of the pharmacy business of Sainsbury based in the U.K. with a net purchase consideration of £128 million (or, approximately \$168 million). This acquisition further enhances our retail pharmacy service capabilities in the U.K. Financial results for Sainsbury since the acquisition date are included in our results of operations within our International pharmaceutical distribution and services business, which is part of our Distribution Solutions segment.

Under the terms of the agreement, on February 29, 2016, we made an advance cash payment of £125 million (or, approximately \$174 million) representing the full purchase consideration, subject to net working capital adjustment, which was included in "Other Noncurrent Assets" within our condensed consolidated balance sheet as of March 31, 2016. The advance payment bore interest at an annual rate of 3.3%, compounded daily, from February 29, 2016 until the acquisition date. Upon the completion of the acquisition, we received an interest payment.

Total provisional fair value of assets acquired and liabilities assumed, excluding goodwill and intangibles, was \$29 million and \$18 million as of the acquisition date. Approximately \$92 million of the adjusted preliminary purchase price allocations has been assigned to goodwill, which primarily reflects the expected future benefits of synergies upon integrating the businesses. Included in the preliminary purchase price allocation are acquired identifiable intangibles of \$65 million primarily representing restrictive pharmacy licenses with a weighted average life of 15 years. The amounts as of the acquisition date are provisional and subject to change within the measurement period as our fair value assessments are finalized.

The fair value of acquired intangibles was primarily determined by applying the income approach, using several significant unobservable inputs for projected cash flows and a discount rate. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance.

Other Acquisitions

During the last two years, we also completed a number of other acquisitions within both of our operating segments. Financial results for our business acquisitions have been included in our condensed consolidated financial statements since their respective acquisition dates. Purchase prices for our business acquisitions have been allocated based on estimated fair values at the date of acquisition.

Goodwill recognized for our business acquisitions is generally not expected to be deductible for tax purposes. However, if we acquire the assets of a company, the goodwill may be deductible for tax purposes.

5. Discontinued Operations

During the fourth quarter of 2015, we committed to a plan to sell our Brazilian pharmaceutical distribution business, which we acquired through our February 2014 acquisition of Celesio, from our Distribution Solutions segment.

Accordingly, the results of operations and cash flows of this business are classified as discontinued operations for all periods presented in our condensed consolidated financial statements.

On January 31, 2016, we entered into an agreement to sell our Brazilian pharmaceutical distribution business to a third party. On May 31, 2016, we completed the sale of this business and recognized an after-tax loss of \$113 million within discontinued operations in the first quarter of 2017 primarily for the settlement of certain indemnification matters as well as the release of the cumulative translation losses. We made a payment of approximately \$100 million related to the sale of this business.

Table of Contents

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

The results of discontinued operations during the third quarters and first nine months of 2017 and 2016 were not material except for the loss recognized upon the disposition of our Brazilian business. As of March 31, 2016, the carrying amounts of total assets and liabilities for this business were \$635 million and \$660 million, included under the captions "Current assets held for sale" and "Current liabilities held for sale" within our condensed consolidated balance sheets.

6. Restructuring

On March 14, 2016, we committed to a restructuring plan to lower our operating costs (the "Cost Alignment Plan"). The Cost Alignment Plan primarily consists of a reduction in workforce, and business process initiatives that will be substantially implemented prior to the end of 2019. Business process initiatives primarily include plans to reduce operating costs of our distribution and pharmacy operations, administrative support functions, and technology platforms, as well as the disposal and abandonment of certain non-core businesses. As a result, we recorded \$229 million of pre-tax charges during the fourth quarter of 2016. The restructuring liabilities were \$222 million at March 31, 2016.

During the third quarter and first nine months of 2017, we recorded pre-tax charges of \$5 million and \$4 million as part of the Cost Alignment Plan, and we made \$18 million and \$89 million of cash payments, primarily related to severance. At December 31, 2016, the restructuring liabilities of \$112 million include \$71 million recorded in other accrued liabilities and \$41 million recorded in other noncurrent liabilities in our condensed consolidated balance sheet.

Under the Cost Alignment Plan, we expect to record total pre-tax charges of approximately \$250 million to \$270 million, of which \$233 million of pre-tax charges have been recorded to date. Estimated remaining charges primarily consist of exit-related costs and accelerated depreciation and amortization, which are largely attributed to our Distribution Solutions segment.

7. Divestiture of Businesses

During the second quarter of 2016, we sold our ZEE Medical business within our Distribution Solutions segment for a total purchase price of \$134 million. We recorded a pre-tax gain from this sale of \$52 million (\$29 million after-tax) during the first nine months of 2016.

During the first quarter of 2016, we sold our nurse triage business within our Technology Solutions segment for net sale proceeds of \$84 million and recorded a pre-tax gain of \$51 million (\$38 million after-tax) from the sale.

These divestitures did not meet the criteria to qualify as a discontinued operation under the amended guidance, which became effective for us in the first quarter of 2016. Accordingly, pre-tax gains from both divestitures were recorded in operating expenses within continuing operations of our condensed consolidated statements of operations. Other than the gain on disposal, pre and after-tax income for these businesses were not material for the third quarters and first nine months of 2017 and 2016.

8. Income Taxes

During the third quarters of 2017 and 2016, income tax expense related to continuing operations was \$131 million and \$204 million and included net discrete tax benefits of \$12 million and \$16 million. During the first nine months of 2017 and 2016, income tax expense related to continuing operations was \$570 million and \$704 million and included net discrete tax benefits of \$69 million and \$45 million. Our discrete tax benefits for the first nine months of 2017 includes a tax benefit of \$47 million related to the adoption of the amended accounting guidance on employee share-based compensation.

The non-cash pre-tax charge of \$290 million to impair the carrying value of goodwill related to our EIS business within our Technology Solutions segment, described in Financial Note 3, "Goodwill Impairment," has an unfavorable

impact on our effective tax rate for the first nine months of 2017. Approximately \$269 million of the total goodwill impairment charge was not deductible. The income tax provision for the first nine months of 2017 includes a tax benefit of \$8 million related to this impairment charge.

During the third quarter of 2016, we recognized \$19 million discrete tax benefit due to a reduction in our deferred tax liabilities as a result of enacted tax law changes in certain foreign jurisdictions. Our discrete tax benefits for the first nine months of 2016 includes a tax benefit of \$25 million associated with the U.S. Tax Court's decision in *Altera Corp. v. Commissioner* related to the treatment of share-based compensation expense in an intercompany cost-sharing agreement.

Table of ContentsMcKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Our reported income tax rates for the third quarters of 2017 and 2016 were 16.8% and 24.1% and for the first nine months of 2017 and 2016 were 25.7% and 27.3%. The fluctuations in our reported income tax rates are primarily due to changes within our business mix, including varying proportions of income attributable to foreign countries that have lower income tax rates, discrete items, and the impact of the intercompany sale of software.

As of December 31, 2016, we had \$437 million of unrecognized tax benefits, of which \$296 million would reduce income tax expense and the effective tax rate, if recognized. Based on the information currently available, we do not anticipate a significant increase or decrease to our unrecognized tax benefits within the next 12 months. However, this may change as we continue to have ongoing negotiations with various taxing authorities throughout the year.

We report interest and penalties on tax deficiencies as income tax expense. We recognized income tax expense of \$3 million during the third quarters of 2017 and 2016; and income tax benefit of \$9 million and income tax expense of \$9 million during the first nine months of 2017 and 2016, before any tax benefit, related to interest and penalties in our condensed consolidated statements of operations. At December 31, 2016 and 2015, before any tax benefits, our accrued interest and penalties on unrecognized tax benefits amounted to \$43 million and \$78 million.

We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. During the first quarter of 2017, we reached an agreement with the Internal Revenue Service (“IRS”) to settle all outstanding issues relating to the fiscal years 2007 through 2009. This settlement did not have a material impact on our provision for income taxes. We are subject to audit by the IRS for fiscal years 2010 through the current fiscal year. We are generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2006 through the current fiscal year.

9. Noncontrolling Interests

Under a domination and profit and loss transfer agreement (the “Domination Agreement”) entered into between McKesson and Celesio AG (“Celesio”) in 2014, McKesson is obligated to pay an annual recurring compensation amount of €0.83 per Celesio share (“Compensation Amount”) to the noncontrolling shareholders of Celesio. Additionally, the noncontrolling interests in Celesio are redeemable at the option of the holder as a result of a right to put their Celesio shares at €22.99 per share (“Put Right”) under the Domination Agreement. Accordingly, the noncontrolling interests in Celesio are presented as “Redeemable Noncontrolling Interests” on the accompanying condensed consolidated balance sheets. The Put Right amount is increased annually for interest in the amount of five percentage points above a base rate published by the German Bundesbank semiannually, less any Compensation Amount or the guaranteed dividend already paid in respect of the relevant time period (“Put Amount”). The Domination Agreement became effective when it was registered in the commercial register of Celesio at the local court of Stuttgart on December 2, 2014.

Subsequent to the Domination Agreement’s registration, certain noncontrolling shareholders of Celesio initiated appraisal proceedings (“Appraisal Proceedings”) with the Stuttgart Regional Court to challenge the Compensation Amount, the guaranteed dividend and/or the Put Amount. If any such Appraisal Proceedings result in an adjustment to the Compensation Amount, the guaranteed dividend and/or the Put Amount, Celesio Holdings Deutschland GmbH & Co. KGaA (formerly known as McKesson Deutschland GmbH & Co. KGaA or Dragonfly GmbH & Co. KGaA) would be required to make certain additional payments for any shortfall to all Celesio noncontrolling shareholders who previously received the guaranteed dividend, Compensation Amount and/or the Put Amount.

The balance of redeemable noncontrolling interests is reported at the greater of its carrying value or its maximum redemption value at each reporting date. The redemption value is the Put Amount adjusted for exchange rate fluctuations each period. There were no material exercises of the Put Right during the third quarter and first nine months of 2017. At December 31, 2016 and March 31, 2016, the carrying value of redeemable noncontrolling interests of \$1.31 billion and \$1.41 billion exceeded the maximum redemption value of \$1.19 billion and \$1.28 billion. At December 31, 2016 and March 31, 2016, we owned approximately 76.0% of Celesio’s outstanding

common shares.

17

Table of ContentsMcKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Changes in redeemable noncontrolling interests were as follows:

| (In millions) | Redeemable Noncontrolling Interests |
|---|---|
| Balance, March 31, 2016 | \$ 1,406 |
| Net income attributable to noncontrolling interests | 33 |
| Other comprehensive loss | (95) |
| Reclassification of recurring compensation to other accrued liabilities | (33) |
| Balance, December 31, 2016 | \$ 1,311 |

There were no material changes in our ownership interests of noncontrolling interests during the first nine months of 2017 and 2016.

10. Earnings Per Common Share

Basic earnings per common share are computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share are computed similar to basic earnings per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

Table of ContentsMcKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

The computations for basic and diluted earnings per common share are as follows:

| | Quarter Ended | | Nine Months | |
|--|---------------|-------|----------------|---------|
| | December 31, | | Ended December | |
| (In millions, except per share amounts) | 2016 | 2015 | 2016 | 2015 |
| Income from continuing operations | \$649 | \$642 | \$1,647 | \$1,877 |
| Net income attributable to noncontrolling interests | (13) | (13) | (48) | (39) |
| Income from continuing operations attributable to McKesson | 636 | 629 | 1,599 | 1,838 |
| Income (loss) from discontinued operations, net of tax | (3) | 5 | (117) | (11) |
| Net income attributable to McKesson | \$633 | \$634 | \$1,482 | \$1,827 |

Weighted average common shares outstanding:

| | | | | |
|----------------------------------|-----|-----|-----|-----|
| Basic | 221 | 230 | 224 | 231 |
| Effect of dilutive securities: | | | | |
| Options to purchase common stock | — | 1 | 1 | 1 |
| Restricted stock units | 1 | 1 | 1 | 2 |
| Diluted | 222 | 232 | 226 | 234 |

Earnings (loss) per common share attributable to McKesson: ⁽¹⁾

| | | | | |
|-------------------------|---------|--------|---------|---------|
| Diluted | | | | |
| Continuing operations | \$2.86 | \$2.71 | \$7.07 | \$7.86 |
| Discontinued operations | (0.01) | 0.02 | (0.51) | (0.05) |
| Total | \$2.85 | \$2.73 | \$6.56 | \$7.81 |
| Basic | | | | |
| Continuing operations | \$2.89 | \$2.74 | \$7.14 | \$7.95 |
| Discontinued operations | (0.02) | 0.02 | (0.52) | (0.04) |
| Total | \$2.87 | \$2.76 | \$6.62 | \$7.91 |

(1) Certain computations may reflect rounding adjustments.

Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based and other restricted stock units. Approximately 2 million and 1 million potentially dilutive securities were excluded from the computations of diluted net earnings per common share for each of the quarters ended December 31, 2016 and 2015 and 2 million and 1 million potentially dilutive securities were excluded from the computations of diluted net earnings per common share for the nine months ended December 31, 2016 and 2015, as they were anti-dilutive.

Table of ContentsMcKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

11. Goodwill and Intangible Assets, Net

Changes in the carrying amount of goodwill were as follows:

| (In millions) | Distribution Solutions | Technology Solutions | Total |
|---|---------------------------|-------------------------|-----------|
| Balance, March 31, 2016 | \$ 7,987 | \$ 1,799 | \$ 9,786 |
| Goodwill acquired | 2,810 | 22 | 2,832 |
| Impairment | — | (290) | (290) |
| Amount reclassified to assets held for sale | (89) | (1,071) | (1,160) |
| Goodwill allocated to disposed businesses | (35) | — | (35) |
| Acquisition accounting, transfers and other adjustments | (100) | — | (100) |
| Foreign currency translation adjustments, net | (415) | (6) | (421) |
| Balance, December 31, 2016 | \$ 10,158 | \$ 454 | \$ 10,612 |

As of December 31, 2016 and March 31, 2016, the accumulated goodwill impairment losses were \$290 million and \$36 million primarily in our Technology Solutions segment. Refer to Financial Note 3, "Goodwill Impairment," for more information on goodwill reclassified to assets held for sale and the impairment charge recorded during the first nine months of 2017.

Information regarding intangible assets is as follows:

| (Dollars in millions) | December 31, 2016 | | | March 31, 2016 | | | |
|----------------------------|---|-----------------------------|-----------------------------|---------------------------|-----------------------------|-----------------------------|---------------------------|
| | Weighted Average Remaining Amortization Period (years) | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount |
| Customer relationships | 9 | \$ 2,743 | \$ (1,225) | \$ 1,518 | \$ 2,652 | \$ (1,324) | \$ 1,328 |
| Service agreements | 14 | 982 | (300) | 682 | 959 | (269) | 690 |
| Pharmacy licenses | 24 | 805 | (141) | 664 | 857 | (121) | 736 |
| Trademarks and trade names | 12 | 770 | (111) | 659 | 314 | (96) | 218 |
| Technology | 1 | 65 | (63) | 2 | 195 | (182) | 13 |
| Other | 5 | 199 | (141) | 58 | 163 | (127) | 36 |
| Total | | \$ 5,564 | \$ (1,981) | \$ 3,583 | \$ 5,140 | \$ (2,119) | \$ 3,021 |

Amortization expense of intangible assets was \$102 million and \$332 million for the third quarter and first nine months of 2017 and \$108 million and \$329 million for the third quarter and first nine months of 2016. Estimated annual amortization expense of these assets is as follows: \$78 million, \$387 million, \$373 million, \$358 million and \$346 million for the remainder of 2017 and each of the succeeding years through 2021 and \$2,041 million thereafter. All intangible assets were subject to amortization as of December 31, 2016 and March 31, 2016.

Table of Contents

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

12. Debt and Financing Activities

Long-Term Debt

Our long-term debt includes both U.S. dollar and foreign currency (primarily Euro) denominated borrowings. At December 31, 2016 and March 31, 2016, \$7,717 million and \$8,107 million of total long-term debt was outstanding, of which \$1,748 million and \$1,610 million were included under the caption “Current portion of long-term debt” within the condensed consolidated balance sheets. On October 18, 2016, we repaid our €350 million Euro-denominated bond (or, approximately \$385 million) at its maturity.

During the third quarter of 2016, we repaid our \$500 million 0.95% notes due December 4, 2015 at maturity. During the second quarter of 2016, we repaid \$400 million of floating rate notes at maturity. During the first quarter of 2016, we repaid a term loan for \$93 million.

Revolving Credit Facilities

We have a syndicated \$3.5 billion senior unsecured revolving credit facility (the “Global Facility”), which has a \$3.15 billion aggregate sublimit of availability in Canadian dollars, British pound sterling and Euros. The Global facility matures on October 22, 2020. Borrowings under the Global Facility bear interest based upon the London Interbank Offered Rate, Canadian Dealer Offered Rate, a prime rate, or alternative overnight rates as applicable, and agreed margins. The Global Facility contains a financial covenant which obligates the Company to maintain a debt to capital ratio of no greater than 65% and other customary investment grade covenants. If we do not comply with these covenants, our ability to use the Global Facility may be suspended and repayment of any outstanding balances under the Global Facility may be required. At December 31, 2016, we were in compliance with all covenants. There were no borrowings outstanding under this facility during the third quarter and first nine months of 2017, and as of December 31, 2016.

We also maintain bilateral credit lines primarily denominated in Euros with a total committed and uncommitted balance of \$238 million. Borrowings and repayments were not material during the first nine months of 2017. During the first nine months of 2016, we borrowed \$631 million and repaid \$633 million under these credit lines primarily related to short-term borrowings. These credit lines have interest rates ranging from 0.18% to 6% plus the relevant floating reference rate. As of December 31, 2016, there was no amount outstanding under bilateral credit lines.

Accounts Receivable Facilities

We previously maintained accounts receivable factoring facilities (the “Factoring Facilities”) denominated in foreign currencies. During the first nine months of 2017 and 2016, we borrowed \$6 million and \$901 million and repaid \$13 million and \$1,037 million in short-term borrowings under these facilities. The Factoring Facilities expired in April 2016. At March 31, 2016, there was \$7 million in secured borrowings outstanding under these facilities.

Commercial Paper

We maintain a commercial paper program to support our working capital requirements and for other general corporate purposes. Under the program, the Company can issue up to \$3.5 billion in outstanding notes. As of December 31, 2016, we had \$1.4 billion commercial paper notes outstanding with the weighted average interest rate of 1.05%. There was no borrowing outstanding under the commercial paper program as of March 31, 2016.

13. Pension Benefits

The net periodic expense for our defined pension benefit plans was \$8 million and \$22 million for the third quarter and first nine months of 2017 and \$15 million and \$46 million for the third quarter and first nine months of 2016.

Cash contributions to these plans were \$6 million and \$16 million for the third quarter and first nine months of 2017 and \$8 million and \$52 million for the third quarter and first nine months of 2016. The projected unit credit method is utilized in measuring net periodic pension expense over the employees’ service life for the pension plans.

Unrecognized actuarial losses exceeding 10% of the greater of the projected benefit obligation or the market value of

assets are amortized straight-line over the average remaining future service periods and expected life expectancy.

Table of Contents

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

14. Hedging Activities

In the normal course of business, we are exposed to interest rate and foreign exchange rate fluctuations. At times, we limit these risks through the use of derivatives such as interest rate swaps, cross currency swaps and foreign currency forward contracts. In accordance with our policy, derivatives are only used for hedging purposes. We do not use derivatives for trading or speculative purposes.

Foreign currency exchange risk

We conduct our business worldwide in U.S. dollars and the functional currencies of our foreign subsidiaries, including Euro, British pound sterling and Canadian dollar. Changes in foreign currency exchange rates could have a material adverse impact on our financial results that are reported in U.S. dollars. We are also exposed to foreign currency exchange rate risk related to our foreign subsidiaries, including intercompany loans denominated in non-functional currencies. We have certain foreign currency exchange rate risk programs that use foreign currency forward contracts and cross currency swaps. These forward contracts and cross currency swaps are generally used to offset the potential income statement effects from intercompany loans denominated in non-functional currencies. These programs reduce but do not entirely eliminate foreign exchange rate risk.

Derivatives Designated as Hedges

At December 31, 2016 and March 31, 2016, we had forward contracts to hedge the U.S. dollar against cash flows denominated in Canadian dollars with total gross notional values of \$323 million, which were designated as cash flow hedges. These contracts will mature between March 2017 and March 2020.

From time to time, we enter into cross currency swaps to convert fixed-rate foreign currency denominated borrowings to fixed-rate U.S. dollar borrowings. For our cross currency swap transactions, we agree with another party to exchange, at specified intervals, one currency for another currency at a fixed exchange rate, generally set at inception, calculated by reference to agreed upon notional amounts. These cross currency swaps are designed to reduce the income statement effects from fluctuations in foreign exchange rates and have been designated as cash flow hedges.

At December 31, 2016 and March 31, 2016, we had cross currency swaps with total gross notional amounts of approximately \$1,839 million and \$546 million, which are designated as cash flow hedges. These swaps will mature between February 2018 and December 2022.

For forward contracts and currency swaps that are designated as cash flow hedges, the effective portion of changes in the fair values of hedges is recorded into accumulated other comprehensive income and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. Gains or losses on these hedges recorded in other comprehensive income and earnings were not material during the third quarters and first nine months of 2017 and 2016.

Derivatives Not Designated as Hedges

At December 31, 2016, we had a number of forward contracts to primarily hedge the U.S. dollar against cash flows denominated in Canadian dollars with total gross notional value of \$882 million. These contracts will mature through January 2017 and none of these contracts were designated for hedge accounting. Gains or losses from these contracts were not material for the third quarter and first nine months of 2017.

We also have a number of forward contracts to primarily hedge the Euro against cash flows denominated in British pound sterling and other European currencies. At December 31, 2016 and March 31, 2016, the total gross notional amounts of these contracts were \$99 million and \$876 million. These contracts will mature through May 2017 and none of these contracts were designated for hedge accounting. Changes in the fair values of contracts not designated as hedges are recorded directly into earnings and accordingly, net losses of \$1 million and net gains of \$4 million for the third quarter and first nine months of 2017 and net losses of \$24 million and \$2 million for the third quarter and first nine months of 2016 were recorded within operating expenses. The gains or losses from these contracts are largely offset by changes in the value of the underlying intercompany foreign currency loans.

Table of ContentsMcKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Information regarding the fair value of derivatives on a gross basis is as follows:

| (In millions) | Balance Sheet Caption | December 31, 2016 | | March 31, 2016 | |
|---|--|---|---|---|---|
| | | Fair Value of Derivative Asset | U.S. Dollar Notional Liability | Fair Value of Derivative Asset | U.S. Dollar Notional Liability |
| Derivatives designated for hedge accounting | | | | | |
| Foreign exchange contracts (current) | Prepaid expenses and other | \$18 | \$ -80 | \$16 | \$ -80 |
| Foreign exchange contracts (non-current) | Other Noncurrent Assets | 51 | — 243 | 46 | — 243 |
| Cross currency swaps (non-current) | Other Noncurrent Assets/Liabilities | 130 | — 1,839 | — 8 | 546 |
| Total | | \$199 | \$ — | \$62 | \$ 8 |
| Derivatives not designated for hedge accounting | | | | | |
| Foreign exchange contracts (current) | Prepaid expenses and other | \$5 | \$ -943 | \$23 | \$ -680 |
| Foreign exchange contracts (current) | Other accrued liabilities | — | — 38 | — | — 196 |
| Total | | \$5 | \$ — | \$23 | \$ — |

Refer to Financial Note 15, "Fair Value Measurements," for more information on these recurring fair value measurements.

15. Fair Value Measurements

At December 31, 2016 and March 31, 2016, the carrying amounts of cash, certain cash equivalents, restricted cash, marketable securities, receivables, drafts and accounts payable, short-term borrowings and other current liabilities approximated their estimated fair values because of the short maturity of these financial instruments.

The fair value of our commercial paper was determined using quoted prices in active markets for identical liabilities, which are considered to be Level 1 inputs.

Our long-term debt is carried at amortized cost. The carrying amounts and estimated fair values of these liabilities were \$7.7 billion and \$8.0 billion at December 31, 2016 and \$8.1 billion and \$8.6 billion at March 31, 2016. The estimated fair value of our long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future.

Assets Measured at Fair Value on a Recurring Basis

Included in cash and cash equivalents at December 31, 2016 and March 31, 2016 were investments in money market funds of \$0.6 billion and \$2.4 billion, which are reported at fair value. The fair value of the money market funds was determined by using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature.

Table of Contents

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Fair values of our forward foreign currency derivatives were determined using quoted market prices of similar instruments in an active market and other observable inputs from available market information. Fair values of our foreign currency swaps were determined using the quoted foreign currency exchange rates and other observable inputs from available market information. These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 14, "Hedging Activities," for more information on our forward foreign currency derivatives including foreign currency forward contracts and swaps.

There were no transfers between Level 1, Level 2 or Level 3 of the fair value hierarchy during the third quarters and first nine months of 2017 and 2016.

Assets Measured at Fair Value on a Nonrecurring Basis

We measure certain long-lived assets at fair value on a nonrecurring basis when they are deemed to be other-than-temporarily impaired. If the cost of an investment exceeds its fair value, we evaluate, among other factors, our intent to hold the investment, general market conditions, the duration and extent to which the fair value is less than cost and the financial outlook for the industry and location. An impairment charge is recorded when the cost of the asset exceeds its fair value and this condition is determined to be other-than-temporary.

At December 31, 2016, assets measured at fair value on a nonrecurring basis consisted of goodwill for a reporting unit within our Technology Solutions segment, as further discussed below. There were no liabilities measured at fair value on a nonrecurring basis at December 31, 2016.

There were no assets or liabilities measured at fair value on a nonrecurring basis at March 31, 2016.

Goodwill

As discussed in Financial Note 3, "Goodwill Impairment," during the first nine months of 2017, we recorded a non-cash pre-tax charge of \$290 million (\$282 million after-tax) to impair the carrying value of goodwill related to our EIS business, which is a reporting unit within our Technology Solutions segment. The impairment primarily resulted from a decline in estimated cash flows. The goodwill impairment test requires us to compare the fair value of the reporting unit to the fair value of the reporting unit's net assets, excluding goodwill but including any unrecognized intangible assets, to determine the implied fair value of goodwill. If the carrying value of goodwill for the reporting unit exceeds the implied fair value of goodwill, an impairment charge is recorded for that excess.

Fair value assessment of the reporting unit and the reporting unit's net assets are considered a Level 3 measurement due to the significance of unobservable inputs developed using company specific information. We considered the market approach as well as income approach using a discount cash flow ("DCF") model to determine the fair value of the reporting unit. The DCF method was used to determine the fair value of intangible assets.

16. Commitments and Contingent Liabilities

In addition to commitments and obligations in the ordinary course of business, we are subject to various claims, including claims with customers and vendors, pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. As described below, many of these proceedings are at preliminary stages and many seek an indeterminate amount of damages.

When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the ultimate loss. However, the likelihood of a loss with respect to a particular contingency is often difficult to predict and determining a meaningful estimate of the loss or a range of loss may not be practicable based on the information available and the potential effect of future events and decisions by third parties that will determine the ultimate resolution of the contingency. Moreover, it is not uncommon for such matters to be resolved over many years, during which time relevant developments and new information must be reevaluated at least quarterly to determine both the likelihood of potential loss and whether it is possible to reasonably estimate a range of possible loss. When a loss is probable but a reasonable estimate cannot be made, disclosure of the proceeding is provided.

Table of Contents

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. As discussed above, development of a meaningful estimate of loss or a range of potential loss is complex when the outcome is directly dependent on negotiations with or decisions by third parties, such as regulatory agencies, the court system and other interested parties. Such factors bear directly on whether it is possible to reasonably estimate a range of potential loss and boundaries of high and low estimates.

Significant developments in previously reported proceedings and in other litigation and claims, since the filing of our 2016 Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the period ended June 30, 2016 are set out below. Unless otherwise stated, we are currently unable to estimate a range of reasonably possible losses for the unresolved proceedings described below. Should any one or a combination of more than one of these proceedings be successful, or should we determine to settle any or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction or be forced to change the manner in which we operate our business, which could have a material adverse impact on our financial position or results of operations.

Litigation, Government Subpoenas and Investigations

As previously disclosed, in the fourth quarter of 2015, the Company reached an agreement in principle with the Drug Enforcement Administration, Department of Justice (“DOJ”) and various U.S. Attorneys’ offices to settle all potential administrative and civil claims relating to investigations about the Company’s suspicious order reporting practices for controlled substances. In January 2017, the final settlement agreements were executed. As part of the settlement, the Company has paid \$150 million in January 2017, which was previously accrued in 2015.

As previously disclosed, on February 23, 2016, the Company removed the action captioned State of West Virginia ex rel. Morrissey v. McKesson Corporation, Civil Action No.: 16-C-1, to the United States District Court for the Southern District of West Virginia (Civil Action No.: 2:16-cv-01772). On March 21, 2016, the Company filed a motion for judgment on the pleadings. On March 24, 2016, the State of West Virginia filed a motion to remand the matter to state court. On January 24, 2017, the court remanded the matter to state court. The court did not rule on the pending motion for judgment on the pleadings.

From time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests also can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements. Examples of such subpoenas and investigations are included in the Company’s 2016 Annual Report on Form 10-K and previously filed Form 10-Qs.

17. Stockholders’ Equity

Each share of the Company’s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to share equally in any dividends declared by the Company’s Board of Directors (the “Board”).

In July 2015, the Company’s quarterly dividend was raised from \$0.24 to \$0.28 per common share for dividends declared after such date, until further action by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company’s future earnings, financial condition, capital requirements and other factors.

Share Repurchase Plans

In October 2015, the Board authorized the repurchase of up to \$2 billion of the Company's common stock. During the third quarter of 2016, we bought 1.9 million shares at an average price per share of \$186.99. During 2016, our share repurchases were completed through open market transactions.

Table of ContentsMcKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

During the third quarter of 2016, we retired 115.5 million or \$7.8 billion of the Company's treasury shares previously repurchased. Under the applicable state law, these shares resume the status of authorized and unissued shares upon retirement. In accordance with our accounting policy, we allocate any excess of share repurchase price over par value between additional paid-in capital and retained earnings. Accordingly, our retained earnings and additional paid-in capital were reduced by \$6.3 billion and \$1.5 billion during the third quarter of 2016.

In October 2016, the Board authorized the repurchase of up to \$4 billion of the Company's common stock. During the third quarter and first nine months of 2017, we repurchased 14 million shares for \$2 billion through open market transactions at an average price per share of \$140.96. The total authorization outstanding for repurchases of the Company's common stock was \$3.0 billion at December 31, 2016.

Other Comprehensive Income (Loss)

Information regarding other comprehensive loss including redeemable noncontrolling interests, net of tax, by component is as follows:

| (In millions) | Quarter Ended December 31, | | Nine Months Ended December 31, | |
|--|-------------------------------|---------|--------------------------------------|---------|
| | 2016 | 2015 | 2016 | 2015 |
| Foreign currency translation adjustments ⁽¹⁾ | | | | |
| Foreign currency translation adjustments arising during period, net of income tax expense (benefit) of nil, \$3, \$1 and \$3 ⁽²⁾ ⁽³⁾ | \$(398) | \$(246) | \$(782) | \$(142) |
| Reclassified to income statement, net of income tax expense of nil, nil, nil and nil ⁽⁴⁾ | — | — | 20 | — |
| | (398) | (246) | (762) | (142) |
| Unrealized gains (losses) on cash flow hedges | | | | |
| Unrealized gains (losses) on cash flow hedges arising during period, net of income tax expense of nil, nil, nil and nil | (14) | (1) | (20) | 5 |
| Changes in retirement-related benefit plans ⁽⁵⁾ | | | | |
| Net actuarial loss and prior service cost arising during the period, net of income tax benefit of nil, nil, nil and \$9 | — | — | — | (28) |
| Amortization of actuarial loss and prior service costs, net of income tax expense of \$1, \$4, \$3 and \$13 ⁽⁶⁾ | 2 | 8 | 6 | 23 |
| Foreign currency translation adjustments and other, net of income tax expense of nil, nil, nil and nil | 6 | 7 | 14 | 3 |
| | 8 | 15 | 20 | (2) |
| Other comprehensive income (loss), net of tax | \$(404) | \$(232) | \$(762) | \$(139) |

Foreign currency translation adjustments result from the conversion of non-U.S. dollar financial statements of our (1) foreign subsidiaries into the Company's reporting currency, U.S. dollars, and were primarily related to our foreign subsidiary, Celesio, during the third quarters and first nine months of 2017 and 2016.

The net foreign currency translation losses during the third quarter and first nine months of 2017 were primarily due to the weakening of the British pound sterling and Euro against the U.S. dollar from April 1, 2016 to December 31, 2016. During the third quarter of 2016, the currency translation losses were primarily (2) due to the weakening of the Euro, British pound sterling and Canadian dollar against the U.S. dollar from October 1, 2015 to December 31, 2015. The net foreign currency translation losses during the first nine months of 2016 were primarily due to the weakening of the Canadian dollars against the U.S. dollar from April 1, 2015 to December 31, 2015.

The third quarter and first nine months of 2017 include net foreign currency translation losses of \$31 million and (3) \$97 million and the third quarter and first nine months of 2016 include net foreign translation losses of \$32 million and \$2 million, which are attributable to redeemable noncontrolling interests.

The first nine months of 2017 includes net foreign currency translation losses of \$20 million reclassified from (4) accumulated other comprehensive loss to loss from discontinued operations, net of tax, within our condensed consolidated statements of operations due to the sale of our Brazilian pharmaceutical distribution business.

The third quarter and first nine months of 2017 include net actuarial losses of \$2 million and \$3 million and the (5) third quarter and first nine months of 2016 include net actuarial gains of \$1 million and losses of \$5 million, which are attributable to redeemable noncontrolling interests.

Pre-tax amount reclassified into cost of sales and operating expenses in our condensed consolidated statements of (6) operations. The related tax expense was reclassified into income tax expense in our condensed consolidated statements of operations.

Table of ContentsMcKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Accumulated Other Comprehensive Income (Loss)

Information regarding changes in our accumulated other comprehensive income (loss), net of tax, by component for the third quarter and first nine months of 2017 is as follows:

| (In millions) | Foreign Currency Translation Adjustments, Net of Tax | Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax | Unrealized Net Gains (Losses) and Other Components of Benefit Plans, Net of Tax | Total Accumulated Other Comprehensive Income (Loss) |
|---|--|--|--|---|
| Balance at September 30, 2016 | \$ (1,621) | \$ (18) | \$ (215) | \$ (1,854) |
| Other comprehensive income (loss) before reclassifications | (398) | (14) | 6 | (406) |
| Amounts reclassified to earnings and other | — | — | 2 | 2 |
| Other comprehensive income (loss) | (398) | (14) | 8 | (404) |
| Less: amounts attributable to redeemable noncontrolling interests | (31) | — | 1 | (30) |
| Other comprehensive income (loss) attributable to McKesson | (367) | (14) | 7 | (374) |
| Balance at December 31, 2016 | \$ (1,988) | \$ (32) | \$ (208) | \$ (2,228) |

| (In millions) | Foreign Currency Translation Adjustments, Net of Tax | Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax | Unrealized Net Gains (Losses) and Other Components of Benefit Plans, Net of Tax | Total Accumulated Other Comprehensive Income (Loss) |
|---|--|--|--|---|
| Balance at March 31, 2016 | \$ (1,323) | \$ (12) | \$ (226) | \$ (1,561) |
| Other comprehensive income (loss) before reclassifications | (782) | (20) | 14 | (788) |
| Amounts reclassified to earnings and other | 20 | — | 6 | 26 |
| Other comprehensive income (loss) | (762) | (20) | 20 | (762) |
| Less: amounts attributable to redeemable noncontrolling interests | (97) | — | 2 | (95) |
| Other comprehensive income (loss) attributable to McKesson | (665) | (20) | 18 | (667) |
| Balance at December 31, 2016 | \$ (1,988) | \$ (32) | \$ (208) | \$ (2,228) |

Table of ContentsMcKESSON CORPORATION
FINANCIAL NOTES (CONCLUDED)
(UNAUDITED)

18. Segment Information

We report our operations in two operating segments: McKesson Distribution Solutions and McKesson Technology Solutions. The factors for determining the reportable segments included the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. We evaluate the performance of our operating segments on a number of measures, including operating profit before interest expense, income taxes and results from discontinued operations.

Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows:

| (In millions) | Quarter Ended | | Nine Months Ended | |
|--|---------------|----------|-------------------|-----------|
| | December 31, | | December 31, | |
| | 2016 | 2015 | 2016 | 2015 |
| Revenues | | | | |
| Distribution Solutions ⁽¹⁾ | | | | |
| North America pharmaceutical distribution and services | \$41,685 | \$39,615 | \$124,271 | \$119,750 |
| International pharmaceutical distribution and services | 6,193 | 6,022 | 18,794 | 17,726 |
| Medical-Surgical distribution and services | 1,558 | 1,568 | 4,657 | 4,579 |
| Total Distribution Solutions | 49,436 | 47,205 | 147,722 | 142,055 |
| Technology Solutions - products and services | 694 | 694 | 2,098 | 2,151 |
| Total Revenues | \$50,130 | \$47,899 | \$149,820 | \$144,206 |
| Operating profit | | | | |
| Distribution Solutions ⁽²⁾⁽³⁾ | \$813 | \$906 | \$2,592 | \$2,742 |
| Technology Solutions ⁽⁴⁾⁽⁵⁾ | 132 | 122 | 126 | 426 |
| Total | 945 | 1,028 | 2,718 | 3,168 |
| Corporate Expenses, Net | (91) | (95) | (270) | (320) |
| Interest Expense | (74) | (87) | (231) | (267) |
| Income from Continuing Operations Before Income Taxes | \$780 | \$846 | \$2,217 | \$2,581 |

(1) Revenues derived from services represent less than 2% of this segment's total revenues.

Distribution Solutions operating profit for the third quarter and first nine months of 2017 include pre-tax credits of \$155 million and \$151 million related to our last-in-first-out ("LIFO") method of accounting for inventories. The third quarter and first nine months of 2016 include pre-tax LIFO charges of \$33 million and \$215 million. LIFO credits were recognized in 2017 primarily due to the lower full year expectations for price increases.

Distribution Solutions operating profit for the first nine months of 2016 includes a pre-tax gain of \$52 million recognized from the 2016 second quarter sale of our ZEE Medical business, and for the first nine months of 2017 and 2016 includes \$142 million and \$76 million of net cash proceeds representing our share of net settlements of antitrust class action lawsuits against drug manufacturers.

Technology Solutions operating profit for the first nine months of 2016 includes a pre-tax gain of \$51 million recognized from the 2016 first quarter sale of our nurse triage business.

Technology Solutions operating profit for the first nine months of 2017 includes a non-cash pre-tax charge of \$290 million for goodwill impairment related to the EIS reporting unit and for the third quarter and first nine months of 2017 includes \$31 million and \$58 million of expenses directly associated with the proposed Healthcare Technology Net Asset Exchange.

19. Subsequent Event

On January 24, 2017, we entered into an agreement to acquire CoverMyMeds LLC ("CMM") for approximately \$1.1 billion and up to an additional \$0.3 billion of contingent consideration payable based on CMM's financial performance

through the end of 2019. CMM provides electronic prior authorization solutions and is headquartered in Columbus, Ohio. The transaction is subject to customary closing conditions, including regulatory review, and is expected to close in the first half of 2018.

Table of Contents

McKESSON CORPORATION
FINANCIAL REVIEW
(UNAUDITED)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

GENERAL

Management's discussion and analysis of financial condition and results of operations, referred to as the Financial Review, is intended to assist the reader in the understanding and assessment of significant changes and trends related to the results of operations and financial position of the Company together with its subsidiaries. This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying financial notes in Item 1 of Part I of this Quarterly Report on Form 10-Q and in Item 8 of Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2016 previously filed with the SEC on May 5, 2016 ("2016 Annual Report").

The Company's fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company's fiscal year.

Certain statements in this report constitute forward-looking statements. See "Factors Affecting Forward-Looking Statements" included in this Quarterly Report on Form 10-Q.

Table of ContentsMcKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

Results of Operations

Overview:

| (Dollars in millions, except per share data) | Quarter Ended | | | Nine Months Ended | | |
|---|---------------|-----------|--------|-------------------|-----------|--------|
| | December 31, | | Change | December 31, | | Change |
| | 2016 | 2015 | | 2016 | 2015 | |
| Revenues | \$50,130 | \$47,899 | 5 % | \$149,820 | \$144,206 | 4 % |
| Gross Profit | \$2,812 | \$2,872 | (2) % | \$8,475 | \$8,564 | (1) % |
| Operating Expenses | \$(1,981) | \$(1,952) | 1 % | \$(6,092) | \$(5,759) | 6 % |
| Income from Continuing Operations Before Income Taxes | \$780 | \$846 | (8) % | \$2,217 | \$2,581 | (14) % |
| Income Tax Expense | (131) | (204) | (36) | (570) | (704) | (19) |
| Income from Continuing Operations | 649 | 642 | 1 | 1,647 | 1,877 | (12) |
| Income (Loss) from Discontinued Operations, Net of Tax | (3) | 5 | (160) | (117) | (11) | 964 |
| Net Income | 646 | 647 | - | 1,530 | 1,866 | (18) |
| Net Income Attributable to Noncontrolling Interests | (13) | (13) | - | (48) | (39) | 23 |
| Net Income Attributable to McKesson Corporation | \$633 | \$634 | - % | \$1,482 | \$1,827 | (19) % |
| Diluted Earnings (Loss) Per Common Share Attributable to McKesson Corporation | | | | | | |
| Continuing Operations | \$2.86 | \$2.71 | 6 % | \$7.07 | \$7.86 | (10) % |
| Discontinued Operations | (0.01) | 0.02 | (150) | (0.51) | (0.05) | 920 |
| Total | \$2.85 | \$2.73 | 4 % | \$6.56 | \$7.81 | (16) % |

Weighted Average Diluted Common Shares 222 232 (4) % 226 234 (3) %

Revenues for the third quarter and first nine months of 2017 increased compared to the same periods a year ago primarily due to market growth, higher revenues associated with our 2017 acquisitions including UDG Healthcare Plc (“UDG”), Biologics, Inc. (“Biologics”), Vantage Oncology Holdings LLC (“Vantage”) and Sainsbury Plc (“Sainsbury”), and expanded business with existing customers within our North America pharmaceutical distribution businesses. These increases were partially offset by customer losses. Market growth includes growing drug utilization, price increases and newly launched products, partially offset by price deflation associated with brand to generic drug conversion. Additionally, our Distribution Solutions segment is experiencing customer consolidation, including business combinations that impact our customers.

Gross profit and gross profit margin for 2017 decreased compared to the same periods a year ago primarily due to weaker pharmaceutical pricing trends, the competitive pricing environment and our mix of business, and for the first nine months of 2017 also due to lower compensation from a branded pharmaceutical manufacturer from our U.S. Pharmaceutical distribution business. These decreases were partially offset by our acquisitions, last-in-first out (“LIFO”) inventory credits and benefits from our global procurement arrangements. Gross profit for 2017 also reflects the impact of previously announced customer consolidation activity. Additionally, gross profit for the first nine months of 2017 and 2016 included \$142 million and \$76 million of cash receipts for our share of antitrust legal settlements. For the third quarters of 2017 and 2016, LIFO inventory adjustments were credits of \$155 million and charges of \$33 million, and for the first nine months of 2017 and 2016, credits of \$151 million and charges of \$215 million. LIFO credits were recognized in 2017 primarily due to lower full year expectations for price increases.

Table of Contents

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

Operating expenses for the third quarter and first nine months of 2017 increased 1% and 6% compared to the same periods a year ago. Excluding foreign currency effects of 4% and 2%, operating expenses increased 5% and 8% for the third quarter and first nine months of 2017 primarily due to our acquisitions, partially offset by cost savings from a cost alignment plan implemented in the fourth quarter of 2016 and our ongoing expense management efforts. Additionally, operating expenses for the first nine months of 2017 included a non-cash pre-tax charge of \$290 million (\$282 million after-tax) for goodwill impairment related to our Enterprise Information Solutions (“EIS”) business within our Technology Solutions segment, as further discussed below. Operating expenses for the third quarter and first nine months of 2017 also include \$31 million and \$58 million of expenses directly associated with the proposed transaction between McKesson and Change Healthcare Holdings, Inc. (“Change Healthcare”), as further discussed below. Operating expenses for the first nine months of 2016 benefited from pre-tax gains of \$103 million (\$67 million after-tax) from the sale of two businesses.

Income from continuing operations before income taxes for the third quarter and first nine months of 2017 decreased compared to the same periods a year ago primarily due to lower operating profit from our Distribution Solutions segment.

Net income for the first nine months of 2017 includes discrete income tax benefits of \$47 million related to the early adoption of the amended accounting guidance on share-based compensation. Net income for the first nine months of 2017 also includes an after-tax loss from discontinued operations of \$113 million, or \$0.50 per diluted share, resulting from the 2017 first quarter sale of our Brazilian pharmaceutical distribution business.

Net income attributable to McKesson Corporation for the third quarters of 2017 and 2016 was \$633 million and \$634 million and for the first nine months of 2017 and 2016 was \$1,482 million and \$1,827 million. Diluted earnings per common share attributable to McKesson for the third quarters of 2017 and 2016 were \$2.85 and \$2.73 and for the first nine months of 2017 and 2016 were \$6.56 and \$7.81.

On June 28, 2016, McKesson entered into a contribution agreement as well as various other agreements (“Agreements”) with Change Healthcare, a Delaware corporation, and others to form a joint venture (“New Company”). Under the terms of the Agreements, McKesson will contribute the majority of its McKesson Technology Solutions businesses (“Core MTS Business”) to the New Company. McKesson will retain its RelayHealth Pharmacy and EIS businesses. Change Healthcare will contribute substantially all of its businesses to the New Company excluding its pharmacy switch and prescription routing businesses. The purpose of the transaction is to create a new healthcare information technology company, which will bring together the complementary strengths of the Core MTS Business and Change Healthcare to provide software and analytics, network solutions and technology-enabled services that will help customers obtain actionable insights, exchange mission-critical information, control costs, optimize revenue opportunities, increase cash flow and effectively navigate the shift to value-based healthcare.

On December 21, 2016, McKesson and Change Healthcare announced that it had received notification that the Department of Justice had closed its review and terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The transaction remains subject to other customary closing conditions. Subject to satisfaction of these other closing conditions, the acquisition is expected to close in the first half of calendar year 2017. Upon formation of the New Company, McKesson and Change Healthcare shareholders are expected to own approximately 70% and 30% of the New Company. The New Company will be jointly governed by McKesson and Change Healthcare shareholders. The Company refers to the foregoing transaction as “Healthcare Technology Net Asset Exchange”.

During the second quarter of 2017, the assets and liabilities of the Core MTS Business to be contributed to the New Company met the criteria to be classified as held for sale. The net asset exchange transaction does not meet the criteria to be reported as a discontinued operation as it does not constitute a significant strategic business shift. Accordingly, at December 31, 2016, \$1.9 billion of assets and \$0.7 billion of liabilities related to the Core MTS Business are

included in “Current assets held for sale” and “Current liabilities held for sale” in the accompanying condensed consolidated balance sheet. Depreciation and amortization related to the long-lived assets ceased as of the date they were determined as held for sale. We expect to recognize a gain upon the closing of the Healthcare Technology Net Asset Exchange.

Table of ContentsMcKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

In conjunction with the proposed Healthcare Technology Net Asset Exchange, we are evaluating strategic options for our EIS business, which is a reporting unit within our McKesson Technology Solutions segment. In the second quarter of 2017, we recorded a provisional non-cash pre-tax charge of \$290 million (\$282 million after-tax) to impair the carrying value of this business' goodwill. We completed our analysis of the goodwill impairment assessment in the third quarter of 2017 and concluded that no further adjustment was needed. Most of the goodwill impairment is not deductible for income tax purposes. The impairment primarily resulted from a decline in estimated cash flows. At December 31, 2016, the remaining goodwill balance for this reporting unit was \$124 million.

On December 28, 2016, we completed our acquisition of Rexall Health of the Katz Group Canada, Inc. for cash purchase consideration of \$2.9 billion Canadian dollars (or, approximately \$2.1 billion U.S. dollars), which was funded from cash on hand. Rexall Health operates approximately 470 retail pharmacies in Canada, particularly in Ontario and Western Canada. As part of the transaction, McKesson agreed to divest stores in 26 local markets that the Competition Bureau of Canada identified during its review of the transaction. We do not anticipate any store closures as a result of these divestitures. Commencing in the fourth quarter of 2017, financial results for Rexall will be included in our North America pharmaceutical distribution and services business within our Distribution Solutions segment.

On January 24, 2017, we entered into an agreement to acquire CoverMyMeds LLC ("CMM") for approximately \$1.1 billion and up to an additional \$0.3 billion of contingent consideration payable based on CMM's financial performance through the end of 2019. CMM provides electronic prior authorization solutions and is headquartered in Columbus, Ohio. The transaction is subject to customary closing conditions, including regulatory review, and expected to close in the first half of 2018.

Refer to Financial Notes 2, 3, 4 and 19 "Proposed Healthcare Technology Net Asset Exchange", "Goodwill Impairment", "Business Combinations" and "Subsequent Event" to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10 Q.

Revenues:

| (Dollars in millions) | Quarter Ended | | | Nine Months Ended | | |
|--|-------------------|-------------------|--------|-------------------|-------------------|--------|
| | December 31, 2016 | December 31, 2015 | Change | December 31, 2016 | December 31, 2015 | Change |
| Distribution Solutions | | | | | | |
| North America pharmaceutical distribution and services | \$41,685 | \$39,615 | 5 % | \$124,271 | \$119,7504 | % |
| International pharmaceutical distribution and services | 6,193 | 6,022 | 3 | 18,794 | 17,726 | 6 |
| Medical-Surgical distribution and services | 1,558 | 1,568 | (1) | 4,657 | 4,579 | 2 |
| Total Distribution Solutions | 49,436 | 47,205 | 5 | 147,722 | 142,055 | 4 |
| Technology Solutions - products and services | 694 | 694 | - | 2,098 | 2,151 | (2) |
| Total Revenues | \$50,130 | \$47,899 | 5 % | \$149,820 | \$144,2064 | % |

Revenues for the third quarter and first nine months of 2017 increased 5% and 4% compared to the same periods a year ago primarily due to our Distribution Solutions segment, which accounted for approximately 99% of our consolidated revenues.

Distribution Solutions

North America pharmaceutical distribution and services revenues for the third quarter and first nine months of 2017 increased primarily due to market growth, higher revenues associated with our 2017 acquisitions including Biologics and Vantage, and expanded business with existing customers. These increases were partially offset by customer losses

and for the third quarter of 2017 also by one less sell day.

Table of ContentsMcKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

International pharmaceutical distribution and services revenues for the third quarter and first nine months of 2017 increased 3% and 6% primarily due to market growth including our acquisitions of UDG and Sainsbury. International revenues were unfavorably impacted by foreign currency effects of 7% and 4% for the third quarter and first nine months of 2017 primarily reflecting a decline in the British pound sterling and Euro against the U.S. dollar.

Medical-Surgical revenues for 2017 benefited from market growth and a small acquisition. Additionally, revenues for the third quarter of 2017 were unfavorably affected by the termination of a long term care contract and lower flu sales. The 2016 second quarter sale of our ZEE Medical business unfavorably affected the revenues for the first nine months of 2017.

Our Distribution Solutions segment is experiencing customer consolidation, including business combinations that impact our customers.

Technology Solutions: Technology Solutions revenues for the third quarter were flat and for the first nine months of 2017 decreased compared to the same periods a year ago. The year-to-date decrease for 2017 was primarily due to a decline in hospital software revenues, the transition of a business to a third party and the sale of a small business in the fourth quarter of 2016. Additionally, revenues for the first nine months of 2017 were also unfavorably affected by the 2016 first quarter sale of our nurse triage business. These decreases were partially offset by higher revenues in our other businesses.

Gross Profit:

| (Dollars in millions) | Quarter Ended December 31, | | | Nine Months Ended December 31, | | |
|----------------------------|-------------------------------|----------------|-----------------|--------------------------------------|----------------|-----------------|
| | 2016 | 2015 | Change | 2016 | 2015 | Change |
| Gross Profit | | | | | | |
| Distribution Solutions | \$2,424 | \$2,511 | (3)% | \$7,333 | \$7,462 | (2)% |
| Technology Solutions | 388 | 361 | 7 | 1,142 | 1,102 | 4 |
| Total | \$2,812 | \$2,872 | (2)% | \$8,475 | \$8,564 | (1)% |
| Gross Profit Margin | | | | | | |
| Distribution Solutions | 4.90 | %5.32 | %(42)bp | 4.96 | %5.25 | %(29)bp |
| Technology Solutions | 55.91 | 52.02 | 389 | 54.43 | 51.23 | 320 |
| Total | 5.61 | %6.00 | %(39)bp | 5.66 | %5.94 | %(28)bp |

bp - basis points

Gross profit and gross profit margin for the third quarter and first nine months of 2017 decreased compared to the same periods a year ago primarily due to a decline in our Distribution Solutions segment.

Distribution Solutions

Distribution Solutions segment's gross profit and gross profit margin for the third quarter and first nine months of 2017 decreased compared to the same periods a year ago primarily due to weaker pharmaceutical pricing trends and the competitive pricing environment and for the first nine months of 2017 also due to lower compensation from a branded pharmaceutical manufacturer from our U.S. Pharmaceutical distribution business. These decreases were partially offset by our acquisitions, LIFO inventory credits and benefits from our global procurement arrangements. Gross profit for 2017 also reflects the impact of previously announced customer consolidation activity. Additionally, gross profit for the first nine months of 2017 and 2016 included \$142 million and \$76 million of cash receipts for our share of antitrust legal settlements. For the third quarters of 2017 and 2016, LIFO inventory adjustments were credits of \$155 million and charges of \$33 million, and for the first nine months of 2017 and 2016, credits of \$151 million and charges of \$215 million.

Table of Contents

McKESSON CORPORATION
 FINANCIAL REVIEW (CONTINUED)
 (UNAUDITED)

Our North America distribution business uses the LIFO method of accounting for the majority of its inventories, which results in cost of sales that more closely reflects replacement cost than under other accounting methods. The business' practice is to pass on to customers published price changes from suppliers. Manufacturers generally provide us with price protection, which limits price-related inventory losses. A LIFO expense is recognized when the net effect of price increases on pharmaceutical and non-pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non-pharmaceutical products held in inventory. Our quarterly LIFO expense or credit is determined based on our estimates of annual LIFO expense which is impacted by expected changes in year-end inventory quantities, product mix and manufacturer pricing practices, which may be influenced by market and other external influences. Changes to any of the above factors could have a material impact to our annual LIFO expense. The actual valuation of inventory under the LIFO method is calculated at the end of the fiscal year. LIFO credits were recognized during the first nine months of 2017 primarily due to lower full year expectations for price increases. LIFO credits are anticipated for full year 2017 primarily due to the expected lower level of price increases.

Technology Solutions

Technology Solutions segment's gross profit for the third quarter and first nine months of 2017 increased compared to the same periods a year ago primarily due to lower severance charges and higher pull through of deferred revenue, partially offset by the prior year sale of a small business. Gross profit for the third quarter of 2017 benefited from lower depreciation and amortization expense related to the Core MTS Business assets, which are now classified as held for sale. Additionally, gross profit margin for 2017 was favorably affected by our ongoing cost management efforts and the prior year sale of our businesses. This segment recorded \$8 million and \$28 million of charges primarily associated with the wind down of a product line during the third quarter and first nine months of 2016. The severance charges were recorded as follows: \$6 million and \$21 million in cost of sales and \$2 million and \$7 million in operating expenses during the third quarter and first nine months of 2016.

Operating Expenses and Other Income, Net:

| (Dollars in millions) | Quarter Ended December 31, | | | Nine Months Ended December 31, | | |
|------------------------|-------------------------------|---------|--------|--------------------------------------|---------|--------|
| | 2016 | 2015 | Change | 2016 | 2015 | Change |
| Operating Expenses | | | | | | |
| Distribution Solutions | \$1,628 | \$1,613 | 1 % | \$4,784 | \$4,750 | 1 % |
| Technology Solutions | 256 | 240 | 7 | 1,017 | 678 | 50 |
| Corporate | 97 | 99 | (2) | 291 | 331 | (12) |
| Total | \$1,981 | \$1,952 | 1 % | \$6,092 | \$5,759 | 6 % |

Operating Expenses as a Percentage of Revenues

| | | | | | | |
|------------------------|-------|-------|----------|-------|-------|----------|
| Distribution Solutions | 3.29 | %3.42 | %(13)bp | 3.24 | %3.34 | %(10)bp |
| Technology Solutions | 36.89 | 34.58 | 231 | 48.47 | 31.52 | 1,695 |
| Total | 3.95 | %4.08 | %(13)bp | 4.07 | %3.99 | %8 bp |

Other Income, Net

| | | | | | | |
|------------------------|------|------|-------|------|------|-------|
| Distribution Solutions | \$17 | \$8 | 113 % | \$43 | \$30 | 43 % |
| Technology Solutions | — | 1 | (100) | 1 | 2 | (50) |
| Corporate | 6 | 4 | 50 | 21 | 11 | 91 |
| Total | \$23 | \$13 | 77 % | \$65 | \$43 | 51 % |

Table of ContentsMcKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

Operating expenses for the third quarter and first nine months of 2017 increased 1% and 6% compared to the same periods a year ago. Excluding foreign currency effects of 4% and 2%, operating expenses increased 5% and 8% for the third quarter and first nine months of 2017 primarily due to our acquisitions, partially offset by cost savings from a cost alignment plan implemented in the fourth quarter of 2016 and our ongoing expense management efforts. Additionally, operating expenses for the first nine months of 2017 include a non-cash pre-tax charge of \$290 million (\$282 million after-tax) to impair the carrying value of goodwill related to our EIS business within our Technology Solutions segment. Operating expenses for the third quarter and first nine months of 2017 also include \$31 million and \$58 million of expenses directly associated with the proposed Healthcare Technology Net Asset Exchange. Operating expenses for the first nine months of 2016 include pre-tax gains of \$103 million from the sale of two businesses. On March 14, 2016, we committed to a restructuring plan to lower our operating costs (the “Cost Alignment Plan”). The Cost Alignment Plan primarily consists of a reduction in workforce and business process initiatives that will be substantially implemented prior to the end of 2019. Business process initiatives primarily include plans to reduce operating costs of our distribution and pharmacy operations, administrative support functions and technology platforms, as well as the disposal or abandonment of certain non-core businesses. The Cost Alignment Plan is expected to incur a total of \$250 million to \$270 million of pre-tax charges, of which \$229 million was recorded in the fourth quarter of 2016 primarily representing severance and employee-related costs. During the third quarter and first nine months of 2017, we recorded pre-tax charges of \$5 million and \$4 million. Estimated remaining charges primarily consist of exit-related costs and accelerated depreciation and amortization, which are largely attributed to our Distribution Solutions segment. We anticipate the Cost Alignment Plan to generate approximately \$170 million to \$190 million of net pre-tax savings during the fiscal year ending March 31, 2017 and an incremental \$70 million to \$90 million of net pre-tax savings during the fiscal year ending March 31, 2018. This cumulative run rate of savings is expected to benefit the company in future years. Our operating expenses benefited from the Cost Alignment Plan beginning the first quarter of 2017.

Distribution Solutions

Distribution Solutions segment’s operating expenses for the third quarter and first nine months of 2017 increased 1% compared to the same periods a year ago. Excluding foreign currency effects of 4% and 3%, operating expenses increased 5% and 4% for the third quarter and first nine months of 2017 primarily due to our acquisitions and for the third quarter of 2017 also due to higher bad debt expense. These increase were partially offset by cost savings from the Cost Alignment Plan including lower compensation and benefit costs and our ongoing expense management efforts. Additionally, operating expenses for 2016 benefited from a \$52 million pre-tax gain on the 2016 second quarter sale of our ZEE Medical business.

Technology Solutions

Technology Solutions segment’s operating expenses for the third quarter increased 7% compared to the same period a year ago primarily due to transaction expenses associated with the proposed Healthcare Technology Net Asset Exchange, partially offset by cost savings from the Cost Alignment Plan and our ongoing expense management efforts. Operating expenses for the first nine months of 2017 increased compared to the same period a year ago primarily due to a non-cash pre-tax goodwill impairment charge of \$290 million and higher severance charges, partially offset by cost savings from the Cost Alignment Plan and our ongoing expense management efforts. Operating expenses for the third quarter and first nine months of 2017 include \$31 million and \$58 million of expenses directly associated with the proposed Healthcare Technology Net Asset Exchange. Additionally, operating expenses for 2016 benefited from a pre-tax gain of \$51 million from the sale of our nurse triage business.

Corporate

Corporate expenses for the third quarter and first nine months of 2017 decreased compared to the same periods a year ago primarily due to cost savings from the Cost Alignment Plan including lower compensation and benefit costs and outside service fees.

Table of ContentsMcKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

Acquisition Expenses and Related Adjustments

Acquisition expenses and related adjustments, which include transaction and integration expenses that are directly related to business acquisitions and the proposed Healthcare Technology Net Asset Exchange, were \$75 million and \$23 million for the third quarters of 2017 and 2016 and \$165 million and \$86 million for the first nine months of 2017 and 2016. These expenses primarily include consulting fees, employee severance and retention incentives and legal fees. Increases in the acquisition-related expenses were primarily due to the proposed Healthcare Technology Net Asset Exchange and our current year acquisitions, partially offset by a decline in expenses associated with our February 2013 acquisition of PSS World Medical, Inc. ("PSSI"). Our integration of PSSI was substantially completed in the first quarter of 2017.

Acquisition expenses and related adjustments were as follows:

| | Quarter Ended December 31, | | Nine Months Ended December 31, | |
|--|-------------------------------------|-------|--|-------|
| (Dollars in millions) | 2016 | 2015 | 2016 | 2015 |
| Operating Expenses | | | | |
| Integration and separation related expenses | \$ 22 | \$ 21 | \$ 67 | \$ 77 |
| Severance, retention and relocation | 7 | — | 18 | 1 |
| Transaction closing expenses | 43 | 1 | 72 | 6 |
| Other Income, Net | 3 | 1 | 8 | 2 |
| Total Acquisition Expenses and Related Adjustments | \$ 75 | \$ 23 | \$ 165 | \$ 86 |

Acquisition expenses and related adjustments by segment were as follows:

| | Quarter Ended December 31, | | Nine Months Ended December 31, | |
|--|-------------------------------------|-------|--|-------|
| (Dollars in millions) | 2016 | 2015 | 2016 | 2015 |
| Operating Expenses and Other Income, Net | | | | |
| Distributions Solutions | \$ 43 | \$ 22 | \$ 103 | \$ 84 |
| Technology Solutions | 33 | — | 58 | — |
| Corporate | (1) | 1 | 4 | 2 |
| Total Acquisition Expenses and Related Adjustments | \$ 75 | \$ 23 | \$ 165 | \$ 86 |

Amortization Expenses of Acquired Intangible Assets

Amortization expenses of acquired intangible assets by segment were as follows:

| | Quarter Ended December 31, | | Nine Months Ended December 31, | |
|------------------------|-------------------------------------|-------|--|--------|
| (Dollars in millions) | 2016 | 2015 | 2016 | 2015 |
| Distribution Solutions | \$ 100 | \$ 97 | \$ 311 | \$ 298 |

| | | | |
|------------------------|-------|-------|-------------|
| Technology Solutions 2 | 11 | 21 | 31 |
| Total | \$102 | \$108 | \$332 \$329 |

Amortization expenses of acquired intangible assets were primarily recorded in operating expenses.

Other Income, Net: Other income, net, for the third quarter and first nine months of 2017 increased compared to the same periods a year ago primarily due to higher interest income and income from our equity investments.

Table of ContentsMcKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

Segment Operating Profit, Corporate Expenses, Net and Interest Expense:

| (Dollars in millions) | Quarter Ended December 31, | | | Nine Months Ended December 31, | | |
|---|-------------------------------|-------|--------|--------------------------------------|---------|--------|
| | 2016 | 2015 | Change | 2016 | 2015 | Change |
| Segment Operating Profit ⁽¹⁾ | | | | | | |
| Distribution Solutions | \$813 | \$906 | (10)% | \$2,592 | \$2,742 | (5)% |
| Technology Solutions ⁽²⁾ | 132 | 122 | 8 | 126 | 426 | (70) |
| Subtotal | 945 | 1,028 | (8) | 2,718 | 3,168 | (14) |
| Corporate Expenses, Net | (91) | (95) | (4) | (270) | (320) | (16) |
| Interest Expense | (74) | (87) | (15) | (231) | (267) | (13) |
| Income from Continuing Operations Before Income Taxes | \$780 | \$846 | (8)% | \$2,217 | \$2,581 | (14)% |

Segment Operating Profit Margin

| | | | | | | |
|------------------------|-------|-------|---------|------|-------|---------|
| Distribution Solutions | 1.64 | %1.92 | %(28)bp | 1.75 | %1.93 | %(18)bp |
| Technology Solutions | 19.02 | 17.58 | 144 | 6.01 | 19.80 | (1,379) |

(1) Segment operating profit includes gross profit, net of operating expenses, as well as other income, net, for our two operating segments.

(2) The first nine months of 2017 include a non-cash pre-tax charge of \$290 million for goodwill impairment related to our EIS business.

Segment Operating Profit

Distribution Solutions: Operating profit and operating profit margin decreased for the third quarter and first nine months of 2017 compared to the same periods a year ago primarily due to lower gross profit. Operating profit for the third quarter and the first nine months of 2017 included lower LIFO expense and for the first nine months of 2017 included higher cash receipts representing our share of antitrust legal settlements. Operating expenses for the first nine months of 2016 included a \$52 million pre-tax gain from the 2016 second quarter sale of our ZEE Medical business.

Technology Solutions: Operating profit and operating profit margin increased for the third quarter of 2017 compared to the same period a year ago primarily due to higher gross profit. Operating profit and operating profit margin decreased for the first nine months of 2017 compared to the same period a year ago primarily due to higher operating expenses including a \$290 million pre-tax charge for goodwill impairment related to our EIS business. Additionally, operating profit for the first nine months of 2016 included a \$51 million pre-tax gain from the 2016 first quarter sale of our nurse triage business.

Corporate: Corporate expenses, net, decreased for the third quarter and first nine months of 2017 primarily due to a decrease in operating expenses.

Interest Expense: Interest expense for the third quarter and first nine months of 2017 decreased primarily due to repayments of debt and certain foreign currency denominated credit facilities.

Income Taxes: Our reported income tax rates for the third quarters of 2017 and 2016 were 16.8% and 24.1% and for the first nine months of 2017 and 2016 were 25.7% and 27.3%. The fluctuations in our reported income tax rates are primarily due to changes within our business mix, including varying proportions of income attributable to foreign countries that have lower income tax rates, discrete items, and the beneficial impact of the intercompany transfer of software described more fully below.

On December 19, 2016, we sold various software and ancillary intellectual property relating to our Technology Solutions business between wholly owned legal entities within the McKesson group that are based in different tax jurisdictions. The transferor entity recognized a gain on the sale of assets that was not subject to income tax in its local jurisdiction, such gain was eliminated upon consolidation. An entity based in the U.S. was the recipient of the software and ancillary intellectual property and is entitled to amortize the fair value of the assets for book and tax purposes. For U.S. GAAP purposes, the tax benefit associated with the amortization of these assets is recognized over the expected remaining lives of the assets. For tax purposes, the fair value of the acquired assets is amortized over a three year period.

Table of Contents

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

Income tax expense for the third quarters of 2017 and 2016 includes net discrete tax benefits of \$12 million and \$16 million and for the first nine months of 2017 and 2016, \$69 million and \$45 million. Our discrete tax benefits for the first nine months of 2017 includes a tax benefit of \$47 million related to the adoption of the amended accounting guidance on employee share-based compensation.

The non-cash pre-tax charge of \$290 million to impair the carrying value of goodwill related to our EIS business within our Technology Solutions segment, described in Financial Note 3, "Goodwill Impairment," has an unfavorable impact on our effective tax rate for the first nine months of 2017. Approximately \$269 million of the total goodwill impairment charge was not tax deductible. The income tax provision for the first nine months of 2017 includes a tax benefit of \$8 million related to this impairment charge.

Our income tax provision for the third quarter of 2016 included \$19 million discrete tax benefit due to a reduction in our deferred tax liabilities as a result of enacted tax law changes in certain foreign jurisdictions. Additionally, our discrete tax benefits for the first nine months of 2016 includes a tax benefit of \$25 million associated with the U.S. Tax Court's decision in *Altera Corp. v. Commissioner* related to the treatment of share-based compensation expense in an intercompany cost-sharing agreement.

Loss from Discontinued Operations, Net of Tax: Loss from discontinued operations, net for the first nine months of 2017 includes an after-tax loss of \$113 million from the sale of our Brazilian pharmaceutical distribution business in the first quarter of 2017. Loss from discontinued operations, net was \$11 million for the first nine months of 2016. Diluted loss per common share from discontinued operations for the first nine months of 2017 and 2016 was \$0.51 and \$0.05.

Net Income Attributable to Noncontrolling Interests: Net income attributable to noncontrolling interests for 2017 primarily represents the accrual of the annual recurring compensation amount of €0.83 per Celesio share that McKesson is obligated to pay to the noncontrolling shareholders of Celesio under a domination and profit and loss transfer agreement (the "Domination Agreement"). Refer to Financial Note 9, "Noncontrolling Interests," to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q for additional information.

Net Income Attributable to McKesson Corporation: Net income attributable to McKesson Corporation was \$633 million and \$634 million, and diluted earnings per common share attributable to McKesson Corporation were \$2.85 and \$2.73 for the third quarters of 2017 and 2016. Net income attributable to McKesson Corporation was \$1,482 million and \$1,827 million, and diluted earnings per common share attributable to McKesson Corporation were \$6.56 and \$7.81 for the first nine months of 2017 and 2016.

Weighted Average Diluted Common Shares Outstanding: Diluted earnings per common share were calculated based on a weighted average number of shares outstanding of 222 million and 232 million for the third quarters of 2017 and 2016 and 226 million and 234 million for the first nine months of 2017 and 2016. Weighted average diluted shares for 2017 decreased from 2016 primarily reflecting common stock repurchases during the third quarter of 2017 and the second half of 2016.

Business Combinations

Refer to Financial Notes 4 and 19, "Business Combinations" and "Subsequent Event," to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10 Q for further information.

New Accounting Pronouncements

New accounting pronouncements that we have recently adopted as well as those that have been recently issued but not yet adopted by us are included in Financial Note 1, "Significant Accounting Policies," to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q.

Table of ContentsMcKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

Financial Condition, Liquidity and Capital Resources

We expect our available cash generated from operations, together with our existing sources of liquidity from our credit facilities and commercial paper program will be sufficient to fund our long-term and short-term capital expenditures, working capital and other cash requirements. In addition, from time to time, we may access the long-term debt capital markets to discharge our other liabilities.

Operating activities generated cash of \$3,309 million and \$566 million during the first nine months of 2017 and 2016. Operating activities for the first nine months of 2017 were affected by higher drafts and accounts payable and increases in receivables primarily associated with revenue growth. Cash flows from operations can be significantly impacted by factors such as timing of receipts from customers, inventory receipts and payments to vendors.

Additionally, working capital is primarily a function of sale and purchase volumes, inventory requirements and vendor payment terms.

Investing activities utilized cash of \$3,619 million and \$228 million during the first nine months of 2017 and 2016.

Investing activities for the first nine months of 2017 include \$4,174 million of cash paid for acquisitions (including \$2.1 billion for Rexall Health), of which \$935 million was prepaid before March 31, 2016 and was released from restricted cash balances. Investing activities for 2017 also include a payment of approximately \$100 million to sell our Brazilian business. Investing activities for the first nine months of 2016 included \$204 million in net proceeds from the sale of businesses.

Financing activities utilized cash of \$1,145 million and \$2,247 million during the first nine months of 2017 and 2016.

Financing activities for the first nine months of 2017 include cash receipts of \$2,803 million and payments of \$1,405 million for short-term borrowings (primarily commercial paper notes). Long-term debt repayments for the first nine months of 2017 were primarily due to the repayment of \$385 million (or €350 million) of a Euro-denominated bond. Financing activities for the first nine months of 2016 included cash receipts of \$1,532 million and payments of \$1,668 million for short-term borrowings. Long-term debt repayments during the first nine months of 2016 were primarily due to the repayment of a \$400 million of floating rate notes in September 2015 and a \$500 million bond in December 2015.

The Company's Board has authorized the repurchase of McKesson's common stock from time-to-time in open market transactions, privately negotiated transactions, accelerated share repurchase programs, or by any combination of such methods. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, restrictions under our debt obligations and other market and economic conditions.

In October 2016, the Board authorized the repurchase of up to \$4 billion of the Company's common stock. During the first nine months of 2017, we repurchased 14 million shares for \$2 billion through open market transactions. The total authorization outstanding for repurchases of the Company's common stock was \$3.0 billion and \$1.0 billion at December 31, 2016 and March 31, 2016.

We believe that our operating cash flow, financial assets and current access to capital and credit markets, including our existing credit facilities, will give us the ability to meet our financing needs for the foreseeable future. However, there can be no assurance that future volatility and disruption in the global capital and credit markets will not impair our liquidity or increase our costs of borrowing.

Selected Measures of Liquidity and Capital Resources

| (Dollars in millions) | December 31, 2016 | March 31, 2016 | |
|--------------------------------------|----------------------|----------------------|---|
| Cash and cash equivalents | \$ 2,434 | \$4,048 | |
| Working capital | 1,094 | 3,366 | |
| Debt to capital ratio ⁽¹⁾ | 47.9 | %43.6 | % |

Return on McKesson stockholders' equity⁽²⁾ 21.6 % 26.0 %

Ratio is computed as total debt divided by the sum of total debt and McKesson stockholders' equity, which (1) excludes noncontrolling and redeemable noncontrolling interests and accumulated other comprehensive income (loss).

Ratio is computed as net income attributable to McKesson Corporation for the last four quarters, divided by a (2) five-quarter average of McKesson stockholders' equity, which excludes noncontrolling and redeemable noncontrolling interests.

Table of Contents

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

Cash equivalents, which are available-for-sale, are carried at fair value. Cash equivalents are primarily invested in AAA rated prime and U.S. government money market funds denominated in U.S. dollars, AAA rated prime money market funds denominated in Euros, AAA rated prime money market funds denominated in British pound sterling, time deposits, bankers' acceptances, and Canadian government debentures.

The remaining cash and cash equivalents are deposited with several financial institutions. We mitigate the risk of our short term investment portfolio by depositing funds with reputable financial institutions and monitoring risk profiles and investment strategies of money market funds.

Our cash and cash equivalents balance as of December 31, 2016 included approximately \$1.8 billion held by our subsidiaries outside of the United States. Our primary intent is to utilize this cash for foreign operations. Although the vast majority of cash held outside the United States is available for repatriation, doing so could subject us to U.S. federal, state and local income tax.

Working capital primarily includes cash and cash equivalents, receivables and inventories net of drafts and accounts payable, short-term borrowings, current portion of long-term debt, deferred revenue and other current liabilities. Our Distribution Solutions segment requires a substantial investment in working capital that is susceptible to large variations during the year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of sales activity and other requirements.

Our debt to capital ratio increased in 2017 primarily reflecting lower McKesson stockholders' equity.

In July 2015, the Company's quarterly dividend was raised from \$0.24 to \$0.28 per common share for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements and other factors.

The carrying value of redeemable noncontrolling interests related to Celesio was \$1.31 billion at December 31, 2016, which exceeded the maximum redemption value of \$1.19 billion. The balance of redeemable noncontrolling interests is reported at the greater of its carrying value or its maximum redemption value at each reporting date. Upon the effectiveness of the Domination Agreement, the noncontrolling shareholders of Celesio received a put right that enables them to put their Celesio shares to McKesson at €22.99 per share, the price of which is increased annually for interest in the amount of 5 percentage points above a base rate published by the German Bundesbank semiannually, less any compensation amount or guaranteed dividend already paid ("Put Amount"). The redemption value is the Put Amount adjusted for exchange rate fluctuations each period. The ultimate amount and timing of any future cash payments related to the Put Amount are uncertain. Additionally, we are obligated to pay an annual recurring compensation of €0.83 per Celesio share (the "Compensation Amount") to the noncontrolling shareholders of Celesio under the Domination Agreement. The Compensation Amount is recognized ratably during the applicable annual period. Refer to Financial Note 9, "Noncontrolling Interests," to the condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q for additional information.

In connection with the transaction, the New Company has received \$6.1 billion of committed financing, including \$1.2 billion bridge loan, from certain banks. The proceeds are expected to be utilized for repayment of the existing debt of Change Healthcare, payments to Change Healthcare shareholders and McKesson including reimbursements of the transaction-related expenses incurred by McKesson and Change Healthcare. Refer to Financial Note 2, "Proposed Healthcare Technology Net Asset Exchange" to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q for additional information.

Credit Resources

We fund our working capital requirements primarily with cash and cash equivalents as well as short-term borrowings from our credit facilities and commercial paper issuance.

Funds necessary for future debt maturities and our other cash requirements are expected to be met by existing cash balances, cash flow from operations, existing credit sources and other capital market transactions. Detailed information regarding our debt and financing activities is included in Financial Note 12, "Debt and Financing Activities," to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q.

Table of Contents

McKESSON CORPORATION
FINANCIAL REVIEW (CONCLUDED)
(UNAUDITED)

FACTORS AFFECTING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of Part I of this report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of these statements can be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans,” “estimates,” or the negative of and other comparable terminology. The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. Although it is not possible to predict or identify all such risks and uncertainties, they may include, but are not limited to, the following factors. The reader should not consider this list to be a complete statement of all potential risks and uncertainties:

- changes in the U.S. healthcare industry and regulatory environment;
- foreign operations subject us to a number of operating, economic, political and regulatory risks;
- changes in the Canadian healthcare industry and regulatory environment;
- general European economic conditions together with austerity measures taken by certain European governments;
- changes in the European regulatory environment with respect to privacy and data protection regulations;
- foreign currency fluctuations;
- the Company’s ability to successfully identify, consummate, finance and integrate strategic acquisitions;
- the Company’s ability to manage and complete divestitures;
- material adverse resolution of pending legal and regulatory proceedings;
- competition;
 - substantial defaults in payments or a material reduction in purchases by, or the loss of, a large customer or group purchasing organization;
- the loss of government contracts as a result of compliance or funding challenges;
- public health issues in the United States or abroad;
- cyberattack, disaster, or malfunction to computer systems;
- the adequacy of insurance to cover property loss or liability claims;
- the Company’s failure to attract and retain customers for its software products and solutions due to integration and implementation challenges, or due to an inability to keep pace with technological advances;
- the Company’s proprietary products and services may not be adequately protected, and its products and solutions may be found to infringe on the rights of others;
- system errors or failure of our technology products and solutions to conform to specifications;
- disaster or other event causing interruption of customer access to the data residing in our service centers;
- the delay or extension of our sales or implementation cycles for external software products;
- changes in circumstances that could impair our goodwill or intangible assets;
- new or revised tax legislation or challenges to our tax positions;
- general economic conditions, including changes in the financial markets that may affect the availability and cost of credit to the Company, its customers or suppliers;
- changes in accounting principles generally accepted in the United States of America;
- withdrawal from participation in one or more multiemployer pension plans or if such plans are reported to have underfunded liabilities;
- expected benefits from our restructuring and business process initiatives;
- difficulties with outsourcing and similar third party relationships;
- new challenges associated with our retail expansion; and
- inability to keep existing retail store locations or open new retail locations in desirable places.

These and other risks and uncertainties are described herein and in other information contained in our publicly available Securities and Exchange Commission filings and press releases. Readers are cautioned not to place undue reliance on forward looking statements, which speak only as of the date such statements were first made. Except to the extent required by law, we undertake no obligation to publicly release the result of any revisions to our forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

Table of Contents

McKESSON CORPORATION

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

We believe there has been no material change in our exposure to risks associated with fluctuations in interest and foreign currency exchange rates as disclosed in our 2016 Annual Report on Form 10-K.

Item 4. Controls and Procedures.

Our Chief Executive Officer and our Chief Financial Officer, with the participation of other members of the Company's management, have evaluated the effectiveness of the Company's "disclosure controls and procedures" (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended ("Exchange Act")) as of the end of the period covered by this quarterly report, and our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.

There were no changes in our "internal control over financial reporting" (as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15 that occurred during our third quarter of 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

The information set forth in Financial Note 16, "Commitments and Contingent Liabilities," to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q is incorporated herein by reference.

Item 1A. Risk Factors.

There have been no material changes during the period covered by this Quarterly Report on Form 10-Q to the risk factors disclosed in Part I, Item 1A, of our 2016 Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Stock repurchases may be made from time to time in open market transactions, privately negotiated transactions, through accelerated share repurchase programs, or by any combination of such methods. The timing of any repurchases will depend on a variety of factors, including corporate and regulatory requirements.

In October 2016, the Board authorized the repurchase of up to \$4 billion of the Company's common stock.

During the third quarter and first nine months of 2017, we repurchased 14 million shares for \$2 billion through open market transactions. The total authorization outstanding for repurchases of the Company's common stock was \$3.0 billion at December 31, 2016

Table of Contents

McKESSON CORPORATION

The following table provides information on the Company's share repurchases during the third quarter of 2017.
Share Repurchases ⁽¹⁾

| (In millions, except price per share) | Total Number of Shares Purchased | Average Price Paid Per Share | Total Number of Shares Purchased As Part of Publicly Announced Program | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs |
|---------------------------------------|----------------------------------|------------------------------|--|---|
| October 1, 2016 – October 31, 2016 | — | \$— | — | \$4,996 |
| November 1, 2016 – November 30, 2016 | 9.0 | 139.30 | 9.0 | 3,736 |
| December 1, 2016 – December 31, 2016 | 5.0 | 143.88 | 5.0 | 2,996 |
| Total | 14.0 | | 14.0 | — |

This table does not include shares tendered to satisfy the exercise price in connection with cashless exercises of (1) employee stock options or shares tendered to satisfy tax withholding obligations in connection with employee equity awards.

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

Not Applicable

Item 5. Other Information.

None

Table of Contents

McKESSON CORPORATION

Item 6. Exhibits.

Exhibit
Number Description

- 31.1 Certification of the Chief Executive Officer Pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of the Chief Financial Officer Pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32† Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

- 101 The following materials from the McKesson Corporation Quarterly Report on Form 10-Q for the quarter ended December 31, 2016, formatted in Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Statements of Operations, (ii) Condensed Consolidated Statements of Comprehensive Income, (iii) Condensed Consolidated Balance Sheets, (iv) Condensed Consolidated Statements of Cash Flows, and (v) related Financial Notes.

Furnished herewith.

Table of Contents

McKESSON CORPORATION

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MCKESSON CORPORATION

Date: January 26, 2017 /s/ James A. Beer
James A. Beer
Executive Vice President and Chief Financial Officer

MCKESSON CORPORATION

Date: January 26, 2017 /s/ Erin M. Lampert
Erin M. Lampert

Senior Vice President and Controller